WO2013187391A1 - COMPOSITION COMPRISING SESAMIN COMPOUND, γ-ORIZANOL AND RICE GERM OIL - Google Patents

COMPOSITION COMPRISING SESAMIN COMPOUND, γ-ORIZANOL AND RICE GERM OIL Download PDF

Info

Publication number
WO2013187391A1
WO2013187391A1 PCT/JP2013/066033 JP2013066033W WO2013187391A1 WO 2013187391 A1 WO2013187391 A1 WO 2013187391A1 JP 2013066033 W JP2013066033 W JP 2013066033W WO 2013187391 A1 WO2013187391 A1 WO 2013187391A1
Authority
WO
WIPO (PCT)
Prior art keywords
oryzanol
sesamin
germ oil
rice germ
composition
Prior art date
Application number
PCT/JP2013/066033
Other languages
French (fr)
Japanese (ja)
Inventor
悠 一本松
佳子 小野
菜美乃 冨森
大輔 竹本
俊明 末安
Original Assignee
サントリーホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サントリーホールディングス株式会社 filed Critical サントリーホールディングス株式会社
Priority to CN201380031469.5A priority Critical patent/CN104394864B/en
Priority to JP2014521336A priority patent/JP6157463B2/en
Publication of WO2013187391A1 publication Critical patent/WO2013187391A1/en
Priority to HK15105560.2A priority patent/HK1204936A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to in vivo absorption promoters of sesamin and compositions such as foods and drinks or pharmaceutical compositions using them.
  • the present invention also relates to the use of the composition as an antioxidant.
  • Sesamin is a kind of lignan compound contained in sesame.
  • sesamin and its stereoisomer episesamin have a blood cholesterol lowering action and a blood neutral lipid lowering action, a liver function improving action, an active oxygen scavenging action, a ⁇ 5 desaturase inhibiting action, a lipid peroxide production.
  • Various physiological activities such as inhibitory action, antihypertensive action, sickness prevention action, breast cancer inhibitory action have been reported (Patent Document 1).
  • lignan compounds including sesamin are hardly soluble in water and are only slightly soluble in organic solvents that can be used for medicine or food. Due to such poor solubility, lignan compounds have a problem that they are difficult to be absorbed in vivo.
  • Patent Documents 1 and 2 As a method for improving the in vivo absorbability of lignan compounds including sesamins, for example, methods using an emulsion have been proposed (Patent Documents 1 and 2). However, there are not many reports of examples in which the in vivo absorbability of sesamin is improved by simply combining with other compounds in a simpler manner.
  • An object of the present invention is to provide a new means for promoting in-vivo absorption of sesamins, which can solve such problems.
  • the present inventor has found that when sesamin is combined with ⁇ -oryzanol and rice germ oil, the absorption of sesamin in the body can be promoted. This effect can be prominent when ⁇ -oryzanol and rice germ oil are used in a specific ratio.
  • the present invention includes, but is not limited to: 1.
  • the composition according to 1, wherein the total weight of the ⁇ -oryzanol: (the total amount of the total weight of the ⁇ -oryzanol and the weight of the rice germ oil) 1: 20 to 1:60. 2a. 3.
  • the in-vivo absorption enhancer or use according to 11, wherein the total weight of the ⁇ -oryzanol: (the total amount of the total weight of the ⁇ -oryzanol and the weight of the rice germ oil) 1: 25 to 1:55.
  • the absorbability of sesamin in the body can be improved.
  • the effect can be remarkable when the amount of the latter two components is set to a specific ratio. Therefore, the physiological activity can be efficiently exhibited without increasing the dose of sesamin.
  • the present invention can remarkably enhance the antioxidant action of a composition containing sesamin, ⁇ -oryzanol and rice germ oil. Therefore, this invention also provides the antioxidant which can exhibit the outstanding antioxidant effect
  • ⁇ -oryzanol is known to have various physiological actions such as blood neutral lipid lowering action, endocrine / autonomic nerve regulating action, gastric mucosa protecting action and the like. Furthermore, sesamin and ⁇ -oryzanol are extremely safe because they are derived from plants. Therefore, the present invention not only improves the absorbability of sesamin compounds, but also provides a food and drink product and a pharmaceutical composition that can be expected to have a useful physiological effect of ⁇ -oryzanol and that can be consumed safely and continuously. .
  • FIG. 1 is a graph showing the amount of sesamin and episesamin absorbed in the intestinal tract.
  • FIG. 2 is a graph showing the AUC of the ⁇ ORAC value.
  • FIG. 3 is a graph showing the AUC of the ⁇ ORAC value.
  • sesamin The sesamin of the present invention is a general term for a series of compounds including sesamin and its analogs.
  • the sesamin analog include episesamin and dioxabicyclo [3.3.0] octane derivatives described in JP-A-4-9331.
  • Specific examples of sesamin can include sesamin, sesaminol, episesaminol, sesamorin and the like, and these stereoisomers or racemates can be used alone or in combination, but in the present invention, , Sesamin and / or episesamin can be suitably used.
  • metabolites of sesamin compounds (for example, described in JP-A No. 2001-139579) are sesamin analogs contained in the sesamin compounds of the present invention as long as the effects of the present invention are exhibited, and are used in the present invention. Can do.
  • sesamin used in the present invention is not limited at all by its form, production method and the like.
  • sesamin extracted from sesame oil by a known method for example, the method described in JP-A-4-9331
  • sesamin extract or concentrate is usually used.
  • commercially available sesame oil (liquid state) can also be used as it is.
  • sesame oil liquid state
  • the sesamin content is low (usually less than 1%), so when trying to formulate the sesamin necessary to obtain the physiological effects of sesamin, per unit dosage of the formulated composition The volume can become too large, which can cause inconveniences.
  • the dosage form (tablets, capsules, etc.) becomes too large, which causes problems in ingestion. Therefore, it is preferable to use a sesamin extract (or sesamin concentrate) from sesame oil from the viewpoint that the amount of intake may be small.
  • the sesamin extract (or sesamin concentrate) may be made tasteless and odorless by a known means such as activated clay treatment.
  • a sesamin concentrate obtained by improving the content of sesamin by extraction and / or purification from a food-derived material such as sesame oil.
  • the degree of concentration may be appropriately set depending on the type of sesamin used and the form of the composition to be blended.
  • a sesamin concentrate concentrated so that the total amount of sesamin is 1 w / w% or more is used.
  • the total sesamin content in the sesamin concentrate is more preferably 20 w / w% or more, further preferably 50 w / w% or more, more preferably 70 w / w% or more, and concentration to 90 w / w% or more (purification). What is done is optimal.
  • the content of sesamin can be measured using any known method such as HPLC.
  • HPLC method for example, the method described in JP2009-155531A can be referred to.
  • ⁇ -oryzanol and rice germ oil One of the effective ingredients for promoting in vivo absorption of sesamin is ⁇ -oryzanol.
  • ⁇ -Oryzanol has blood neutral lipid lowering action (Geriant.med. 19, 1812-1840, 1981), endocrine / autonomic nerve regulating action (Japanese Pharmacology, 75 (4), 399-403, 1979), Various physiological effects such as gastric mucosal protective action (Nippon Pharmacological Journal, 84 (6), 537-542, 1984) are known, and purified products are used to treat hyperlipidemia and psychosomatic disorders (menopause, It is approved as a medicine for treating irritable bowel syndrome.
  • the ⁇ -oryzanol used in the present invention is a generic name for ferulic acid obtained by ester-linking triterpene alcohol or sterol.
  • triterpene alcohol examples include cycloartol, 24-methylenecycloartanol, cycloartanol, and cyclopranol.
  • sterol examples include campesterol, stigmasterol, ⁇ -sitosterol, and the like. It can be illustrated. In the present invention, these compounds can be used alone or as a mixture.
  • a method for quantifying ⁇ -oryzanol a known method such as a UV absorbance method or an HPLC method can be appropriately used.
  • the sample is dissolved in heptane and the absorbance is measured at the maximum absorption wavelength near 315 nm, as described in the “Quasi-drug raw material standard” and “Food additive other than chemically synthesized products”. This can be quantified.
  • ⁇ -Oryzanol is known to be contained in brown rice, corn, barley and the like. ⁇ -oryzanol is also contained in rice bran oil, which is an oil extracted from brown rice.
  • ⁇ -oryzanol is also contained in rice germ oil, which is another component effective for promoting in vivo absorption of sesamins.
  • Rice germ oil is oil extracted from rice germ, and usually contains about 1.0 to 1.5 w / w% of ⁇ -oryzanol (this concentration is the amount of rice including the weight of ⁇ -oryzanol). (Based on the total weight of the germ oil).
  • the content of rice germ oil can be measured using any known method.
  • the content of rice germ oil can be measured using the content of sterols characteristically contained in rice germ oil or rice germ oil concentrate and the content ratio of various sterols as an index.
  • rice germ oil contains more bound sterols than free sterols, it may be possible to determine whether a composition contains rice germ oil based on the sterol composition. Moreover, since the content of campesterol and stigmasterol in rice germ oil is relatively high, these contents may be used as an index for measuring the content of rice germ oil.
  • ⁇ -Oryzanol and rice germ oil used in the present invention are not limited at all by the origin, form, production method and the like.
  • ⁇ -oryzanol For example, commercially available rice germ oil or the like can be used as it is for ⁇ -oryzanol, but as described above, the content of ⁇ -oryzanol is not high. Therefore, it is not sufficient to add ⁇ -oryzanol and rice germ oil in a proportion as described later. Therefore, instead of or in addition, it is preferable to use one having a high ⁇ -oryzanol content, for example, a ⁇ -oryzanol concentrate from rice bran oil, rice germ oil or the like.
  • the total ⁇ -oryzanol content in the ⁇ -oryzanol concentrate is preferably 2 w / w% or more, more preferably 30 w / w% or more (these concentrations are ⁇ -Based on the total weight of the concentrate including the weight of oryzanol).
  • a concentrate of ⁇ -oryzanol is industrially obtained by extracting from rice bran oil or rice germ oil with an organic solvent or purifying after resin treatment.
  • rice germ oil gamma 30 (Tsukino) Food Industry Co., Ltd.)
  • ⁇ -oryzanol, oryzadorim V-50 rice bran oil, brown rice germ oil (Oryza Oil Co., Ltd.).
  • Rice germ oil contains, for example, oryzal oil S-1 (1.2% to 1.5% ⁇ -oryzanol (this concentration is based on the total amount of rice germ oil including the amount of ⁇ -oryzanol)). Ichimaru Falcos), rice germ oil PRO-15 containing 1.0 to 1.5% ⁇ -oryzanol (this concentration is based on the total amount of rice germ oil including the amount of ⁇ -oryzanol) No. Food Industry Co., Ltd.).
  • composition containing sesamin, ⁇ -oryzanol and rice germ oil Composition containing sesamin, ⁇ -oryzanol and rice germ oil
  • the combination of sesamin, ⁇ -oryzanol and rice germ oil can improve the in vivo absorbability of sesamin. And while being able to exhibit the physiological activity efficiently, health promotion can be aimed at by the physiological effect of each component.
  • the amount and ratio of each component in the composition containing the sesamin of the present invention, ⁇ -oryzanol and rice germ oil are as follows. May be selected as appropriate within the range in which the bioactivity is promoted and the physiological activity is efficiently exhibited.
  • the ratio of the total weight of ⁇ -oryzanol to the total weight of ⁇ -oryzanol and the weight of rice germ oil, if expected to enhance the absorption of sesamin in the body Is from 1: 4 to 1:66, preferably from 1: 8.7 to 1:62, more preferably from 1:20 to 1:60, more preferably from 1:25 to 1:55, more preferably 1:32. To 1:54 or 1: 32.4 to 53.2, more preferably 1:32 to 1:49.
  • the weight of the rice germ oil described in relation to the present invention is the total amount including the weight of ⁇ -oryzanol unless otherwise specified. Without the weight of ⁇ -oryzanol from the total amount.
  • the total weight of ⁇ -oryzanol when the total weight of sesamin contained is 1 is preferably 0.3 or more, more preferably 0.4 or more, more preferably 0.6 or more, more preferably 0.69 or more, more preferably 0.8 or more, and even more preferably 1.0 or more.
  • it is preferably 5.0 or less, more preferably 3.0 or less, more preferably 1.6 or less, more preferably 1.5 or less, more preferably 1.4 or less, more preferably Is 1.39 or less, more preferably 1.2 or less, more preferably 1.1 or less, more preferably 1.06 or less.
  • the present invention includes all combinations of these upper and lower limits.
  • Examples of the preferred total weight range of ⁇ -oryzanol when the total weight of sesamin is 1 are as follows: 0.3 to 5.0, 0.3 to 3.0, 0.3 to 1.6, 0.3 to 1.5, 0.3 to 1.4, 0.3 to 1.39, 0. 3 to 1.2, 0.3 to 1.1, 0.3 to 1.06; 0.4 to 5.0, 0.4 to 3.0, 0.4 to 1.6, 0.4 to 1.5, 0.4 to 1.4, 0.4 to 1.39, 0. 4 to 1.2, 0.4 to 1.1, 0.4 to 1.06; 0.6 to 5.0, 0.6 to 3.0, 0.6 to 1.6, 0.6 to 1.5, 0.6 to 1.4, 0.6 to 1.39, 0.
  • sesamin is blended in an amount of about 1 to 100 mg, preferably 1 to 50 mg, more preferably about 3 to 30 mg, depending on the total weight of the composition.
  • ⁇ -oryzanol can be blended in an amount of about 1 to 100 mg, preferably 1 to 60 mg, more preferably about 3 to 30 mg.
  • Rice germ oil can be blended in an amount of about 1 to 5000 mg, preferably 10 to 1000 mg, more preferably about 30 to 500 mg.
  • the typical total mixing ratio of sesamin in the composition of the present invention is 1 w / w% or more, preferably 1 to 50 w / w%, more preferably 1 to 10 w / w%.
  • the typical total blending ratio of ⁇ -oryzanol is 0.1 to 50 w / w%, preferably 0.5 to 30 w / w%, more preferably 1 to 10 w / w% with respect to the total amount of the composition. is there.
  • a typical total blending ratio of rice germ oil is 5 to 99 w / w%, preferably 20 to 98 w / w%, more preferably 50 to 95 w / w% with respect to the total amount of the composition.
  • the typical total blending ratio of sesamin is 0.001 w / w% or more, preferably 0.001 to 0.5 w / w%. More preferably, it is 0.001 to 0.05 w / w%, and the typical total blending ratio of ⁇ -oryzanol is 0.0001 to 0.1 w / w%, preferably 0.
  • the typical total blending ratio of rice germ oil is 0.05 to 5 w / w based on the total amount of the composition %, Preferably 0.1 to 2.5 w / w%, more preferably 0.2 to 1 w / w%.
  • the form and intake route of the composition of the present invention are not particularly limited. However, in the present invention, when ingested for the purpose of promoting health, it is preferably ingested as an oral composition.
  • composition of the present invention may contain any desired component in addition to sesamins, ⁇ -oryzanol, and rice germ oil as long as the effect is not impaired.
  • vitamins such as vitamin E and vitamin C, minerals, hormones, nutritional ingredients, physiologically active ingredients such as fragrances, emulsifiers, tonicity agents (isotonic agents), buffers, Solubilizing agents, preservatives, stabilizers, antioxidants and the like can be appropriately blended.
  • the composition of the present invention can be used as an antioxidant, that is, a composition for exerting an antioxidant action in vivo due to its excellent antioxidant action.
  • the use of antioxidants is, for example, for eliminating active oxygen in vivo, improving liver function, suppressing lipid peroxide production in vivo, improving energy metabolism, or preventing or preventing the following diseases or conditions: Can lead: skin wrinkles, skin blemishes, skin sag, fatigue, metabolic syndrome, diabetes, arteriosclerosis, hypertension, cancer, inflammation, or aging. Therefore, the antioxidant of the present invention is also effective in these applications.
  • the present invention is an in vivo absorption enhancer of sesamin containing ⁇ -oryzanol and rice germ oil as active ingredients.
  • the present invention also relates to the use of a composition containing ⁇ -oryzanol and rice germ oil as active ingredients for the production of an in vivo absorption enhancer of sesamins.
  • the present invention also relates to a method for promoting in vivo absorption of sesamins, the method comprising administering the sesamins, ⁇ -oryzanol, and rice germ oil.
  • Subjects to be administered include mammals such as humans in need of such enhanced absorption in the body.
  • the use ratio, blending ratio, blending amount, intake amount, etc. of sesamin, ⁇ -oryzanol and rice germ oil in the in vivo absorption enhancer, composition and method include sesamin, ⁇ -oryzanol and rice germ oil. It can determine suitably based on the above-mentioned numerical value regarding the composition to do.
  • the types of sesamin, ⁇ -oryzanol and rice germ oil used are the same.
  • Food / beverage products and pharmaceuticals are used for food / beverage products (functional foods, health supplements, functional nutrition foods, special-purpose foods, foods for specified health use, dietary supplements, diet foods, health It is preferable to provide foods, supplements, etc.) and pharmaceuticals.
  • Such foods and drinks and pharmaceuticals include food and drink compositions and pharmaceutical compositions containing sesamins, ⁇ -oryzanol and rice germ oil, and foods and drinks and pharmaceuticals containing or added to the composition. Also included are foods and drinks and pharmaceuticals that contain or add sesamin absorption enhancers containing ⁇ -oryzanol and rice germ oil as active ingredients.
  • the food and drink and the medicine may be pet food processed as pet food, animal feed, and veterinary medicine.
  • Food / beverage products and pharmaceuticals containing sesamin, ⁇ -oryzanol and rice germ oil have blood cholesterol lowering action, blood neutral lipid lowering action, liver function improving action, active oxygen scavenging action, ⁇ 5 desaturase inhibiting action
  • sesamin can be used to obtain various physiological actions considered to be effective, such as lipid peroxide production inhibitory action, antihypertensive action, sickness prevention action, breast cancer inhibitory action and the like.
  • foods and drinks and pharmaceuticals which are sesamin in vivo absorption promoters containing ⁇ -oryzanol and rice germ oil can be used to allow sesamins to efficiently exhibit the various physiological functions as described above.
  • composition of the present invention is provided as a food or drink
  • the form is provided in the form of health food such as tablets, capsules, powders, granules, drinks (including solutions and suspensions). It can also be provided in the form of soft drinks, tea drinks, dairy products such as yogurt and lactic acid bacteria drinks, seasonings, processed foods, desserts, confectionery (eg gum, candy, jelly), It is not limited to these.
  • the administration form may be oral administration, administration may be in the form of injections, etc., as long as a known formulation suitable for each administration is appropriately used.
  • formulations suitable for oral administration include, but are not limited to, tablets, capsules, powders, granules, solutions, suspensions, syrups and the like.
  • sesamin, ⁇ -oryzanol and rice germ oil are formulated individually, and they are taken almost simultaneously, or after taking one preparation, while taking the other preparation,
  • the in vivo absorption promoting action of sesamins intended by the present invention can be obtained.
  • a kit containing a sesamin in vivo absorption enhancer and a sesamin-containing composition containing ⁇ -oryzanol and rice germ oil together or separately is also intended by the present invention.
  • Each component separately contained in the kit may be taken at the same time, or may be taken sequentially or separately.
  • the numerical range represented by the upper limit value and the lower limit value in this specification that is, “lower limit value to upper limit value” includes the lower limit value and the upper limit value.
  • the range represented by “1-2” includes 1 and 2.
  • Example 1 Examination of absorbability by inversion intestinal model ⁇ Experimental method> SD male rats (7 weeks old) were acclimated in the test environment and used in the experiments. After laparotomy and blood removal under anesthesia, the small intestine (mainly jejunum) of about 15 cm was immediately removed from the pylorus and divided into two. One side is tied with a thread, the outside and inside are inverted, and the adjustment solution (inner solution: NaCl 140 mM, CaCl 2 0.1 mM, MgCl 2 0.5 mM, D-mannose 40 mM, Ascorbic acid 0.8 mM, 10 mM Tris, pH 7. Satisfying 4) and tied the other side to produce a 5 cm inverted intestinal tract.
  • the adjustment solution inner solution: NaCl 140 mM, CaCl 2 0.1 mM, MgCl 2 0.5 mM, D-mannose 40 mM, Ascorbic acid 0.8 mM, 10 mM Tris, pH 7. Sat
  • rice germ oil rice germ oil PRO-15: ⁇ -oryzanol 1.5%, rice germ oil 98.5% , Tsukino Food Industry Co., Ltd.
  • 4250 mg heated and mixed to be uniform. That is, in the composition administered to the control group, the weight ratio of ⁇ -oryzanol: ( ⁇ -oryzanol + rice germ oil) was 1: 3.3. In the composition administered to the test group, the weight ratio of ⁇ -oryzanol: ( ⁇ -oryzanol + rice germ oil) was 1: 32.4.
  • Example 2 Formulation Example (Formulation Example 1) Granule Sesamin 0.75g 10g rice germ oil containing ⁇ -oryzanol (containing 25%) Tocopherol acetate 50g Silica anhydride 20g 110g corn starch After uniformly mixing the above, 100 ml of 10% hydroxypropylcellulose / ethanol solution was added, kneaded as usual, extruded and dried to obtain granules.
  • Example 3 Examination of absorbability and antioxidant capacity by animal test -1 ⁇ Method of experiment> Ten SD male rats (7 weeks old) were purchased from Oriental Bioservice, and acclimated in the test environment for 1 week, and then divided into 5 control groups and 5 test groups.
  • the weight ratio of ⁇ -oryzanol: ( ⁇ -oryzanol + rice germ oil) was 1: 3.3 in the control group and 1: 32.4 in the test group.
  • blood was collected from the tail vein with a heparin blood collection tube, and a plasma sample was obtained by centrifugation (8000 rpm, 10 min). The oxidation ability was measured.
  • ORAC Oxygen Radical Absorbance Capacity method
  • FIG. 2 shows the AUC of the ⁇ ORAC value. From FIG. 2, it was confirmed that the AUC of the ⁇ ORAC value of the test group was significantly increased as compared with the control group. From the above, it is clear that the antioxidant capacity is remarkably increased by reducing the ratio of the weight of ⁇ -oryzanol to the total weight of ⁇ -oryzanol and rice germ oil from the ratio of 1: 3.3 in the control group. It became. Since sesamin is known to exhibit an antioxidant action in vivo, this increase in antioxidant capacity is considered to support the promotion of in vivo absorption of sesamin.
  • Example 4 Examination of absorbability and antioxidant capacity by animal test-2 ⁇ Method of experiment>
  • the weight ratio of ⁇ -oryzanol: ( ⁇ -oryzanol + rice germ oil) was 1:67 in the control group and 1: 53.2 in the test group.
  • blood was collected from the tail vein with a heparin blood collection tube, and a plasma sample was obtained by centrifugation (8000 rpm, 10 min). Was measured.
  • Plasma antioxidant capacity was measured in the same manner as in Example 3.
  • FIG. 3 shows the AUC of the ⁇ ORAC value (the definition is as described above). From FIG. 3, it was confirmed that the AUC of the ⁇ ORAC value of the test group was significantly increased as compared with the control group. From the above, it has been clarified that the antioxidant capacity is remarkably increased by increasing the ratio of the weight of ⁇ -oryzanol to the total weight of ⁇ -oryzanol and rice germ oil from the ratio of 1:67 in the control group. It was. This increase in antioxidant capacity is thought to support the promotion of sesamin absorption in the body.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The present invention relates to a combination of a sesamin compound, γ-orizanol and a rice germ oil.

Description

セサミン類とγ－オリザノールと米胚芽油とを含有する組成物Composition containing sesamin, γ-oryzanol and rice germ oil
　本発明は、セサミン類の体内吸収促進剤、及びそれらを利用する飲食品又は医薬組成物等の組成物に関する。また、本発明は、当該組成物を抗酸化剤として用いることにも関する。 The present invention relates to in vivo absorption promoters of sesamin and compositions such as foods and drinks or pharmaceutical compositions using them. The present invention also relates to the use of the composition as an antioxidant.
　セサミン類はゴマに含有されるリグナン化合物の一種である。なかでもセサミンとその立体異性体であるエピセサミンに関しては、血中コレステロール低下作用及び血中中性脂質低下作用、肝機能改善作用、活性酸素消去作用、Δ５不飽和化酵素阻害作用、過酸化脂質生成抑制作用、抗高血圧作用、悪酔防止作用、乳癌抑制作用等の種々の生理活性が報告されている（特許文献１）。 Sesamin is a kind of lignan compound contained in sesame. Among them, sesamin and its stereoisomer episesamin have a blood cholesterol lowering action and a blood neutral lipid lowering action, a liver function improving action, an active oxygen scavenging action, a Δ5 desaturase inhibiting action, a lipid peroxide production. Various physiological activities such as inhibitory action, antihypertensive action, sickness prevention action, breast cancer inhibitory action have been reported (Patent Document 1).
　しかしなら、セサミン類を包含するリグナン類化合物は、水に殆ど溶解しない上、医薬用又は食用に使用可能な有機溶媒に対してもある程度しか溶解しない。このような難溶性のため、リグナン類化合物は生体内で吸収されにくいという問題を有する。 However, lignan compounds including sesamin are hardly soluble in water and are only slightly soluble in organic solvents that can be used for medicine or food. Due to such poor solubility, lignan compounds have a problem that they are difficult to be absorbed in vivo.
　セサミン類を包含するリグナン類化合物の体内吸収性を向上させる方法としては、例えばエマルジョンを利用する方法が提案されている（特許文献１及び２）。しかしながら、より簡単な方法、例えば、他の化合物と組合せるだけでセサミン類の体内吸収性を向上させた例の報告は多くない。 As a method for improving the in vivo absorbability of lignan compounds including sesamins, for example, methods using an emulsion have been proposed (Patent Documents 1 and 2). However, there are not many reports of examples in which the in vivo absorbability of sesamin is improved by simply combining with other compounds in a simpler manner.
　一方、セサミン類とγ－オリザノールとを含有する組成物が知られている（特許文献３）。また、セサミン類と米胚芽油とを含有する組成物も知られている（特許文献４）。しかしながら、これらの組成物がセサミン類の体内吸収性を向上させるかどうかは明らかとされていない。
ＷＯ２００６／１０６９２６ ＷＯ２００８／０４４５５０ 特開２００９－７３７４９号公報 ＷＯ２００７／０３７３８５ On the other hand, a composition containing sesamin and γ-oryzanol is known (Patent Document 3). Moreover, the composition containing sesamin and rice germ oil is also known (patent document 4). However, it is not clear whether these compositions improve the in vivo absorbability of sesamins.
WO2006 / 106926 WO2008 / 044550 JP 2009-73749 A WO2007 / 037385
　吸収性向上を目的としてエマルジョンを形成させるためには、脂溶性物質を均一に乳化させる必要があり、また複雑な工程を必要とすることからコスト高につながるといった問題もあった。本発明の課題は、このような問題点を解決することのできる、セサミン類の体内吸収を促進するための新たな手段を提供することである。 In order to form an emulsion for the purpose of improving absorbability, it is necessary to uniformly emulsify the fat-soluble substance, and there is also a problem that a complicated process is required, leading to high costs. An object of the present invention is to provide a new means for promoting in-vivo absorption of sesamins, which can solve such problems.
　本発明者は、上記課題を解決するために鋭意検討した結果、セサミン類を、γ－オリザノール及び米胚芽油と組み合わせると、セサミン類の体内吸収が促進され得ることを見出した。この効果は、γ－オリザノールと米胚芽油を特定比率で用いると顕著となり得る。 As a result of intensive studies to solve the above problems, the present inventor has found that when sesamin is combined with γ-oryzanol and rice germ oil, the absorption of sesamin in the body can be promoted. This effect can be prominent when γ-oryzanol and rice germ oil are used in a specific ratio.
　従って、本発明は、以下のものを含むが、これらに限定されない。
１．少なくとも一種のセサミン類と、少なくとも一種のγ－オリザノールと、米胚芽油とを含有する組成物であって、当該γ－オリザノールの総重量：（当該γ－オリザノールの総重量と当該米胚芽油の重量の合計量）＝１：４～１：６６である、組成物。
２．前記γ－オリザノールの総重量：（前記γ－オリザノールの総重量と前記米胚芽油の重量の合計量）＝１：２０～１：６０である、１に記載の組成物。
２ａ．前記γ－オリザノールの総重量：（前記γ－オリザノールの総重量と前記米胚芽油の重量の合計量）＝１：２５～１：５５である、２に記載の組成物。
２ｂ．前記γ－オリザノールの総重量：（前記γ－オリザノールの総重量と前記米胚芽油の重量の合計量）＝１：３２～１：５４である、２ａに記載の組成物。
３．前記セサミン類の総重量を１とした場合の前記γ－オリザノールの総重量が０．３以上である１～２ｂのいずれかに記載の組成物。
４．前記セサミン類がセサミンおよび／またはエピセサミンである、１～３のいずれかに記載の組成物。
５．経口用である、１～４のいずれかに記載の組成物。
６．飲食物である、１～５のいずれかに記載の組成物。
７．抗酸化剤である、１～６のいずれかに記載の組成物。
８．少なくとも一種のγ－オリザノールと米胚芽油とを有効成分として含有する、少なくとも一種のセサミン類の体内吸収促進剤。
９．少なくとも一種のγ－オリザノールと米胚芽油とを有効成分として含有する組成物の、少なくとも一種のセサミン類の体内吸収促進剤の製造のための使用。
１０．前記γ－オリザノールの総重量：（前記γ－オリザノールの総重量と前記米胚芽油の重量の合計量）＝１：４～１：６６である、８に記載の体内吸収促進剤又は９に記載の使用。
１１．前記γ－オリザノールの総重量：（前記γ－オリザノールの総重量と前記米胚芽油の重量の合計量）＝１：２０～１：６０である、１０に記載の体内吸収促進剤又は使用。
１１ａ．前記γ－オリザノールの総重量：（前記γ－オリザノールの総重量と前記米胚芽油の重量の合計量）＝１：２５～１：５５である、１１に記載の体内吸収促進剤又は使用。
１１ｂ．前記γ－オリザノールの総重量：（前記γ－オリザノールの総重量と前記米胚芽油の重量の合計量）＝１：３２～１：５４である、１１ａに記載の体内吸収促進剤又は使用。
１２．前記セサミン類の総重量を１とした場合の前記γ－オリザノールの総重量が０．３以上である、８～１１ｂのいずれかに記載の体内吸収促進剤又は使用。
１３．前記セサミン類がセサミンおよび／またはエピセサミンである、８～１２のいずれかに記載の体内吸収促進剤又は使用。
１４．前記体内吸収促進剤が経口用である、８～１３のいずれかに記載の体内吸収促進剤又は使用。
１５．セサミン類の総量が組成物全量に対して１ｗ／ｗ％以上である、１～７のいずれかに記載の組成物。
１６．少なくとも一種のセサミン類の体内吸収を促進するための方法であって、当該セサミン類と、少なくとも一種のγ－オリザノールと、米胚芽油とを投与することを含む方法。 Accordingly, the present invention includes, but is not limited to:
1. A composition comprising at least one sesamin, at least one γ-oryzanol and rice germ oil, wherein the total weight of the γ-oryzanol: (the total weight of the γ-oryzanol and the rice germ oil Total composition of weight) = 1: 4 to 1:66.
2. 2. The composition according to 1, wherein the total weight of the γ-oryzanol: (the total amount of the total weight of the γ-oryzanol and the weight of the rice germ oil) = 1: 20 to 1:60.
2a. 3. The composition according to 2, wherein the total weight of the γ-oryzanol: (the total amount of the total weight of the γ-oryzanol and the weight of the rice germ oil) = 1: 25 to 1:55.
2b. The composition according to 2a, wherein the total weight of the γ-oryzanol: (the total amount of the total weight of the γ-oryzanol and the weight of the rice germ oil) = 1: 32 to 1:54.
3. The composition according to any one of 1 to 2b, wherein the total weight of the γ-oryzanol is 0.3 or more when the total weight of the sesamin is 1.
4). 4. The composition according to any one of 1 to 3, wherein the sesamin is sesamin and / or episesamin.
5. 5. The composition according to any one of 1 to 4, which is for oral use.
6). 6. The composition according to any one of 1 to 5, which is a food or drink.
7). 7. The composition according to any one of 1 to 6, which is an antioxidant.
8). A body absorption enhancer for at least one sesamin containing at least one γ-oryzanol and rice germ oil as active ingredients.
9. Use of a composition containing at least one γ-oryzanol and rice germ oil as active ingredients for the production of an in-vivo absorption enhancer of at least one sesamin.
10. The total weight of the γ-oryzanol: (the total amount of the total weight of the γ-oryzanol and the weight of the rice germ oil) = 1: 4 to 1:66 Use of.
11. 11. The in-vivo absorption enhancer or use according to 10, wherein the total weight of the γ-oryzanol: (the total amount of the total weight of the γ-oryzanol and the weight of the rice germ oil) = 1: 20 to 1:60.
11a. 12. The in-vivo absorption enhancer or use according to 11, wherein the total weight of the γ-oryzanol: (the total amount of the total weight of the γ-oryzanol and the weight of the rice germ oil) = 1: 25 to 1:55.
11b. The in vivo absorption enhancer or use according to 11a, wherein the total weight of the γ-oryzanol: (the total amount of the total weight of the γ-oryzanol and the weight of the rice germ oil) = 1: 32 to 1:54.
12 The in-vivo absorption enhancer or use according to any one of 8 to 11b, wherein the total weight of the γ-oryzanol is 0.3 or more when the total weight of the sesamin is 1.
13. The in-vivo absorption enhancer or use according to any one of 8 to 12, wherein the sesamin is sesamin and / or episesamin.
14 The in-vivo absorption enhancer or use according to any of 8 to 13, wherein the in-vivo absorption enhancer is for oral use.
15. 8. The composition according to any one of 1 to 7, wherein the total amount of sesamin is 1 w / w% or more based on the total amount of the composition.
16. A method for promoting in-vivo absorption of at least one sesamin, the method comprising administering the sesamin, at least one γ-oryzanol, and rice germ oil.
　本発明によると、セサミン類と、γ－オリザノール及び米胚芽油とを組合せると、セサミン類の体内吸収性が向上され得る。その効果は、後者２成分の量を特定比率にすると顕著となり得る。従って、セサミン類の投与量を増加させることなく、その生理活性を効率よく発揮させることが可能となる。また、本発明は、セサミン類と、γ－オリザノール及び米胚芽油を含む組成物の抗酸化作用を著しく高めることもできる。従って、本発明は、優れた抗酸化作用を発揮することのできる抗酸化剤も提供する。 According to the present invention, when sesamin is combined with γ-oryzanol and rice germ oil, the absorbability of sesamin in the body can be improved. The effect can be remarkable when the amount of the latter two components is set to a specific ratio. Therefore, the physiological activity can be efficiently exhibited without increasing the dose of sesamin. In addition, the present invention can remarkably enhance the antioxidant action of a composition containing sesamin, γ-oryzanol and rice germ oil. Therefore, this invention also provides the antioxidant which can exhibit the outstanding antioxidant effect | action.
　また、γ－オリザノールは、血中中性脂質低下作用、内分泌・自律神経調節作用、胃粘膜保護作用などの様々な生理作用を有することが知られている。さらに、セサミン類及びγ－オリザノールは、植物由来であるため極めて安全性が高い。従って、本発明は、セサミン類の吸収性を向上させるだけでなく、γ－オリザノールの有用な生理作用も期待でき、かつ安全で継続摂取可能な飲食品、医薬用組成物を提供することができる。 Γ-oryzanol is known to have various physiological actions such as blood neutral lipid lowering action, endocrine / autonomic nerve regulating action, gastric mucosa protecting action and the like. Furthermore, sesamin and γ-oryzanol are extremely safe because they are derived from plants. Therefore, the present invention not only improves the absorbability of sesamin compounds, but also provides a food and drink product and a pharmaceutical composition that can be expected to have a useful physiological effect of γ-oryzanol and that can be consumed safely and continuously. .
図１は、腸管内に吸収されたセサミン及びエピセサミンの量を示すグラフである。FIG. 1 is a graph showing the amount of sesamin and episesamin absorbed in the intestinal tract. 図２は、ΔＯＲＡＣ値のＡＵＣを示すグラフである。FIG. 2 is a graph showing the AUC of the ΔORAC value. 図３は、ΔＯＲＡＣ値のＡＵＣを示すグラフである。FIG. 3 is a graph showing the AUC of the ΔORAC value.
発明の実施するための形態BEST MODE FOR CARRYING OUT THE INVENTION
　（セサミン類）
　本発明のセサミン類とは、セサミン及びその類縁体を含む一連の化合物の総称である。前記のセサミン類縁体としては、エピセサミンの他、例えば特開平４－９３３１号公報に記載されたジオキサビシクロ〔３．３．０〕オクタン誘導体がある。セサミン類の具体例としては、セサミン、セサミノール、エピセサミノール、セサモリン等を例示でき、これらの立体異性体又はラセミ体を単独で、または混合して使用することができるが、本発明においては、セサミン及び／又はエピセサミンを好適に用いることができる。また、セサミン類の代謝体（例えば、特開２００１－１３９５７９号公報に記載）も、本発明の効果を示す限り、本発明のセサミン類に含まれるセサミン類縁体であり、本発明に使用することができる。 (Sesamin)
The sesamin of the present invention is a general term for a series of compounds including sesamin and its analogs. Examples of the sesamin analog include episesamin and dioxabicyclo [3.3.0] octane derivatives described in JP-A-4-9331. Specific examples of sesamin can include sesamin, sesaminol, episesaminol, sesamorin and the like, and these stereoisomers or racemates can be used alone or in combination, but in the present invention, , Sesamin and / or episesamin can be suitably used. In addition, metabolites of sesamin compounds (for example, described in JP-A No. 2001-139579) are sesamin analogs contained in the sesamin compounds of the present invention as long as the effects of the present invention are exhibited, and are used in the present invention. Can do.
　本発明に用いるセサミン類は、その形態や製造方法等によって、何ら制限されるものではない。例えば、セサミン類としてセサミンを選択した場合には、通常、ゴマ油から公知の方法（例えば、特開平４－９３３１号公報に記載された方法）によって抽出したセサミン（セサミン抽出物または濃縮物という）を用いることもできるが、市販のゴマ油（液状）をそのまま用いることもできる。しかしながら、ゴマ油を用いた場合には、セサミン含量が低い（通常、１％未満）ため、セサミンの生理作用を得るのに必要なセサミンを配合しようとすると、処方される組成物の単位投与当りの体積が大きくなり過ぎるため、摂取に不都合を生じることがある。特に、経口投与用に製剤化した場合は、製剤（錠剤、カプセルなど）が大きくなり過ぎて摂取に支障が生じる。したがって、摂取量が少なくてよいという観点からもゴマ油からのセサミン抽出物（又はセサミン濃縮物）を用いることが好ましい。なお、ゴマ油特有の風味が官能的に好ましくないと評価されることもあることから、セサミン抽出物（又はセサミン濃縮物）を公知の手段、例えば活性白土処理等により無味無臭としてもよい。 The sesamin used in the present invention is not limited at all by its form, production method and the like. For example, when sesamin is selected as the sesamin, sesamin extracted from sesame oil by a known method (for example, the method described in JP-A-4-9331) (referred to as sesamin extract or concentrate) is usually used. Although it can also be used, commercially available sesame oil (liquid state) can also be used as it is. However, when sesame oil is used, the sesamin content is low (usually less than 1%), so when trying to formulate the sesamin necessary to obtain the physiological effects of sesamin, per unit dosage of the formulated composition The volume can become too large, which can cause inconveniences. In particular, when formulated for oral administration, the dosage form (tablets, capsules, etc.) becomes too large, which causes problems in ingestion. Therefore, it is preferable to use a sesamin extract (or sesamin concentrate) from sesame oil from the viewpoint that the amount of intake may be small. In addition, since the flavor peculiar to sesame oil may be evaluated to be sensory unfavorable, the sesamin extract (or sesamin concentrate) may be made tasteless and odorless by a known means such as activated clay treatment.
　このように、セサミン類としては、ゴマ油等の食品由来の素材から抽出及び／又は精製によりセサミン類の含有濃度を向上させて得られるセサミン類濃縮物を用いるのが好ましい。濃縮の度合いは、用いるセサミン類の種類や配合する組成物の形態により適宜設定すればよいが、通常、セサミン類が総量で１ｗ／ｗ％以上となるように濃縮されたセサミン類濃縮物を用いるのが好ましい。セサミン類濃縮物中のセサミン類総含量は、２０ｗ／ｗ％以上がより好ましく、さらに５０ｗ／ｗ％以上が好ましく、さらにまた７０ｗ／ｗ％以上が好ましく、９０ｗ／ｗ％以上まで濃縮（精製）されたものが最適である。 Thus, as the sesamin, it is preferable to use a sesamin concentrate obtained by improving the content of sesamin by extraction and / or purification from a food-derived material such as sesame oil. The degree of concentration may be appropriately set depending on the type of sesamin used and the form of the composition to be blended. Usually, a sesamin concentrate concentrated so that the total amount of sesamin is 1 w / w% or more is used. Is preferred. The total sesamin content in the sesamin concentrate is more preferably 20 w / w% or more, further preferably 50 w / w% or more, more preferably 70 w / w% or more, and concentration to 90 w / w% or more (purification). What is done is optimal.
　セサミン類の含有量は、ＨＰＬＣ法等の公知のいずれかの方法を用いて測定できる。ＨＰＬＣ法に関しては、例えば、特開２００９－１５５３１２号公報に記載の方法等を参考にすることができる。 The content of sesamin can be measured using any known method such as HPLC. Regarding the HPLC method, for example, the method described in JP2009-155531A can be referred to.
　（γ－オリザノール及び米胚芽油）
　セサミン類の体内吸収を促進するのに有効な成分の一つはγ-オリザノールである。γ－オリザノールには血中中性脂質低下作用（Geriant.med. 19, 1812-1840, 1981）や、内分泌・自律神経調節作用（日薬理誌、75(4)、399-403, 1979）、胃粘膜保護作用（日薬理誌、84(6)、537-542, 1984）などの様々な生理作用が知られており、精製されたものは高脂血症治療剤や心身症（更年期障害、過敏性大腸症候群）治療剤などの医薬品として認可されている。本発明において用いられるγ－オリザノールは、フェルラ酸にトリテルペンアルコールまたはステロールがエステル結合したものの総称をさす。前記のトリテルペンアルコールとしては、例えば、シクロアルテノール、２４-メチレンシクロアルタノール、シクロアルタノール、シクロプラノール等を挙げることができ、ステロールとしては、カンペステロール、スチグマステロール、β-シトステロール等を例示することができる。本発明においては、これらの化合物を単独で用いることもできるし、混合物として使用することもできる。γ-オリザノールの定量法としては、ＵＶ吸光度法やＨＰＬＣ法等の公知の方法を適宜用いることができる。例えば、「医薬部外品原料規格」や「化学的合成品以外の食品添加物　自主規格」に記載されている通り、サンプルをヘプタンに溶解し、３１５ｎｍ付近における吸収の極大波長で吸光度を測定することにより、定量することができる。 (Γ-oryzanol and rice germ oil)
One of the effective ingredients for promoting in vivo absorption of sesamin is γ-oryzanol. γ-Oryzanol has blood neutral lipid lowering action (Geriant.med. 19, 1812-1840, 1981), endocrine / autonomic nerve regulating action (Japanese Pharmacology, 75 (4), 399-403, 1979), Various physiological effects such as gastric mucosal protective action (Nippon Pharmacological Journal, 84 (6), 537-542, 1984) are known, and purified products are used to treat hyperlipidemia and psychosomatic disorders (menopause, It is approved as a medicine for treating irritable bowel syndrome. The γ-oryzanol used in the present invention is a generic name for ferulic acid obtained by ester-linking triterpene alcohol or sterol. Examples of the triterpene alcohol include cycloartenol, 24-methylenecycloartanol, cycloartanol, and cyclopranol. Examples of the sterol include campesterol, stigmasterol, β-sitosterol, and the like. It can be illustrated. In the present invention, these compounds can be used alone or as a mixture. As a method for quantifying γ-oryzanol, a known method such as a UV absorbance method or an HPLC method can be appropriately used. For example, the sample is dissolved in heptane and the absorbance is measured at the maximum absorption wavelength near 315 nm, as described in the “Quasi-drug raw material standard” and “Food additive other than chemically synthesized products”. This can be quantified.
　γ－オリザノールは、玄米、コーン、大麦等に含まれることが知られている。γ－オリザノールは、玄米から抽出された油である米糠油にも含まれている。 Γ-Oryzanol is known to be contained in brown rice, corn, barley and the like. γ-oryzanol is also contained in rice bran oil, which is an oil extracted from brown rice.
　また、γ－オリザノールは、セサミン類の体内吸収を促進するのに有効なもう一つの成分である米胚芽油にも含まれている。米胚芽油は、米の胚芽から抽出された油であり、それには、通常、γ－オリザノールが１．０～１．５ｗ／ｗ％程度（この濃度は、γ－オリザノールの重量を含めた米胚芽油の総重量を基準とする）含まれていると言われている。米胚芽油の含有量は、公知のいずれかの方法を用いて測定できる。例えば、米胚芽油の含有量は、米胚芽油もしくは米胚芽油濃縮物に特徴的に含まれるステロールの含有量、ならびに各種ステロールの含有比率を指標として測定することが可能である。具体的には、米胚芽油は遊離型ステロールと比較して結合型ステロールを多く含むため、ステロール組成に基づいて、ある組成物が米胚芽油を含むかどうかを判断できる可能性がある。また、米胚芽油のカンペステロールやスチグマステロールの含有量は比較的高いため、これらの含有量を、米胚芽油の含有量の測定のための指標とすることができる可能性がある。 Γ-oryzanol is also contained in rice germ oil, which is another component effective for promoting in vivo absorption of sesamins. Rice germ oil is oil extracted from rice germ, and usually contains about 1.0 to 1.5 w / w% of γ-oryzanol (this concentration is the amount of rice including the weight of γ-oryzanol). (Based on the total weight of the germ oil). The content of rice germ oil can be measured using any known method. For example, the content of rice germ oil can be measured using the content of sterols characteristically contained in rice germ oil or rice germ oil concentrate and the content ratio of various sterols as an index. Specifically, since rice germ oil contains more bound sterols than free sterols, it may be possible to determine whether a composition contains rice germ oil based on the sterol composition. Moreover, since the content of campesterol and stigmasterol in rice germ oil is relatively high, these contents may be used as an index for measuring the content of rice germ oil.
　本発明に用いるγ－オリザノール及び米胚芽油は、その由来や形態、製造方法等によって、何ら制限されるものではない。 Γ-Oryzanol and rice germ oil used in the present invention are not limited at all by the origin, form, production method and the like.
　例えば、γ－オリザノールは、市販の米胚芽油等をそのまま用いることもできるが、上述のとおり、それに含まれるγ－オリザノールの含有量は高くない。従って、後述するような比率でγ－オリザノールと米胚芽油とを配合させるためには、これだけを配合するだけでは十分でない。そのため、それに代えて、又は追加的に、γ-オリザノール含量の高いものを用いるのが好ましく、例えば米糠油や米胚芽油等からのγ－オリザノール濃縮物を用いることが好ましい。γ－オリザノールの濃縮物を用いる場合、γ－オリザノール濃縮物中のγ－オリザノール含量としては、総量として、２ｗ／ｗ％以上が好ましく、３０ｗ／ｗ％以上がより好ましい（これらの濃度は、γ－オリザノールの重量を含めた濃縮物の総重量を基準とする）。このようなγ－オリザノールの濃縮物は、工業的には、米糠油や米胚芽油から有機溶剤で抽出、あるいは樹脂処理後に精製して得られており、例えば、米胚芽油ガンマ３０（築野食品工業株式会社）や、γ-オリザノール、オリザドリムＶ－５０、コメヌカ油、玄米胚芽油（オリザ油化株式会社）として入手可能である。 For example, commercially available rice germ oil or the like can be used as it is for γ-oryzanol, but as described above, the content of γ-oryzanol is not high. Therefore, it is not sufficient to add γ-oryzanol and rice germ oil in a proportion as described later. Therefore, instead of or in addition, it is preferable to use one having a high γ-oryzanol content, for example, a γ-oryzanol concentrate from rice bran oil, rice germ oil or the like. When a γ-oryzanol concentrate is used, the total γ-oryzanol content in the γ-oryzanol concentrate is preferably 2 w / w% or more, more preferably 30 w / w% or more (these concentrations are γ -Based on the total weight of the concentrate including the weight of oryzanol). Such a concentrate of γ-oryzanol is industrially obtained by extracting from rice bran oil or rice germ oil with an organic solvent or purifying after resin treatment. For example, rice germ oil gamma 30 (Tsukino) Food Industry Co., Ltd.), γ-oryzanol, oryzadorim V-50, rice bran oil, brown rice germ oil (Oryza Oil Co., Ltd.).
　米胚芽油は、例えば、γ－オリザノールを１．２～１．５％（この濃度は、γ－オリザノールの量を含めた米胚芽油の総量を基準とする）含有するオリザオイルＳ－１（一丸ファルコス社）、γ－オリザノールを１．０～１．５％（この濃度は、γ－オリザノールの量を含めた米胚芽油の総量を基準とする）含有する米胚芽油ＰＲＯ－１５（築野食品工業株式会社）等の名称にて市販されている。 Rice germ oil contains, for example, oryzal oil S-1 (1.2% to 1.5% γ-oryzanol (this concentration is based on the total amount of rice germ oil including the amount of γ-oryzanol)). Ichimaru Falcos), rice germ oil PRO-15 containing 1.0 to 1.5% γ-oryzanol (this concentration is based on the total amount of rice germ oil including the amount of γ-oryzanol) No. Food Industry Co., Ltd.).
　（セサミン類とγ－オリザノールと米胚芽油とを含有する組成物）
　本発明によると、セサミン類とγ－オリザノールと米胚芽油とを組み合わせるとセサミン類の体内吸収性の向上が達成され得る。そして、その生理活性を効率的に発揮させることができるとともに、それぞれの成分の生理作用により、健康増進を図ることができる。 (Composition containing sesamin, γ-oryzanol and rice germ oil)
According to the present invention, the combination of sesamin, γ-oryzanol and rice germ oil can improve the in vivo absorbability of sesamin. And while being able to exhibit the physiological activity efficiently, health promotion can be aimed at by the physiological effect of each component.
　本発明のセサミン類とγ－オリザノールと米胚芽油とを含有する組成物（飲食品、医薬組成物等）中の各成分の配合量及び配合比率は、後述するように、セサミン類の体内吸収が促進され、生理活性が効率的に発揮される範囲で適宜選択すればよい。 The amount and ratio of each component in the composition containing the sesamin of the present invention, γ-oryzanol and rice germ oil (food and beverage, pharmaceutical composition, etc.) are as follows. May be selected as appropriate within the range in which the bioactivity is promoted and the physiological activity is efficiently exhibited.
　本発明の組成物においては、セサミン類の体内吸収促進効果を期待するのであれば、含有されるγ－オリザノールの総重量対γ－オリザノールの総重量と米胚芽油の重量との合計量の比率は、１：４～１：６６、好ましくは１：８．７～１：６２、より好ましくは１：２０～１：６０、より好ましくは１：２５～１：５５、より好ましくは１：３２～１：５４又は１：３２．４～５３．２、より好ましくは１：３２～１：４９である。尚、使用される米胚芽油にγ－オリザノールが含まれている場合には、本発明に関して記載される米胚芽油の重量は、異なる定めがない限り、γ－オリザノールの重量を含めた総量ではなく、総量からγ－オリザノールの重量を除いた重量を意味する。 In the composition of the present invention, the ratio of the total weight of γ-oryzanol to the total weight of γ-oryzanol and the weight of rice germ oil, if expected to enhance the absorption of sesamin in the body Is from 1: 4 to 1:66, preferably from 1: 8.7 to 1:62, more preferably from 1:20 to 1:60, more preferably from 1:25 to 1:55, more preferably 1:32. To 1:54 or 1: 32.4 to 53.2, more preferably 1:32 to 1:49. When the rice germ oil used contains γ-oryzanol, the weight of the rice germ oil described in relation to the present invention is the total amount including the weight of γ-oryzanol unless otherwise specified. Without the weight of γ-oryzanol from the total amount.
　また、含有されるセサミン類の総重量を１とした場合のγ－オリザノールの総重量は、好ましくは０．３以上、より好ましくは０．４以上、より好ましくは０．６以上、より好ましくは０．６９以上、より好ましくは０．８以上、さらにより好ましくは１．０以上である。その値に上限は特にないが、好ましくは５．０以下、より好ましくは３．０以下、より好ましくは１．６以下、より好ましくは１．５以下、より好ましくは１．４以下、より好ましくは１．３９以下、より好ましくは１．２以下、より好ましくは１．１以下、より好ましくは１．０６以下である。本発明は、これらの上限値及び下限値の全ての組合せを含む。セサミン類の総重量を１とした場合のγ－オリザノールの好ましい総重量の範囲の例は以下の通りである：
０．３～５．０、０．３～３．０、０．３～１．６、０．３～１．５、０．３～１．４、０．３～１．３９、０．３～１．２、０．３～１．１、０．３～１．０６；
０．４～５．０、０．４～３．０、０．４～１．６、０．４～１．５、０．４～１．４、０．４～１．３９、０．４～１．２、０．４～１．１、０．４～１．０６；
０．６～５．０、０．６～３．０、０．６～１．６、０．６～１．５、０．６～１．４、０．６～１．３９、０．６～１．２、０．６～１．１、０．６～１．０６；
０．６９～５．０、０．６９～３．０、０．６９～１．６、０．６９～１．５、０．６９～１．４、０．６９～１．３９、０．６９～１．２、０．６９～１．１、０．６９～１．０６；
０．８～５．０、０．８～３．０、０．８～１．６、０．８～１．５、０．８～１．４、０．８～１．３９、０．８～１．２、０．８～１．１、０．８～１．０６；
１．０～５．０、１．０～３．０、１．０～１．６、１．０～１．５、１．０～１．４、１．０～１．３９、１．０～１．２、１．０～１．１、１．０～１．０６。
　特に好ましい範囲は、例えば、０．６９～１．３９、０．６９～１．０６である。 The total weight of γ-oryzanol when the total weight of sesamin contained is 1 is preferably 0.3 or more, more preferably 0.4 or more, more preferably 0.6 or more, more preferably 0.69 or more, more preferably 0.8 or more, and even more preferably 1.0 or more. Although there is no particular upper limit to the value, it is preferably 5.0 or less, more preferably 3.0 or less, more preferably 1.6 or less, more preferably 1.5 or less, more preferably 1.4 or less, more preferably Is 1.39 or less, more preferably 1.2 or less, more preferably 1.1 or less, more preferably 1.06 or less. The present invention includes all combinations of these upper and lower limits. Examples of the preferred total weight range of γ-oryzanol when the total weight of sesamin is 1 are as follows:
0.3 to 5.0, 0.3 to 3.0, 0.3 to 1.6, 0.3 to 1.5, 0.3 to 1.4, 0.3 to 1.39, 0. 3 to 1.2, 0.3 to 1.1, 0.3 to 1.06;
0.4 to 5.0, 0.4 to 3.0, 0.4 to 1.6, 0.4 to 1.5, 0.4 to 1.4, 0.4 to 1.39, 0. 4 to 1.2, 0.4 to 1.1, 0.4 to 1.06;
0.6 to 5.0, 0.6 to 3.0, 0.6 to 1.6, 0.6 to 1.5, 0.6 to 1.4, 0.6 to 1.39, 0. 6-1.2, 0.6-1.1, 0.6-1.06;
0.69 to 5.0, 0.69 to 3.0, 0.69 to 1.6, 0.69 to 1.5, 0.69 to 1.4, 0.69 to 1.39, 0. 69-1.2, 0.69-1.1, 0.69-1.06;
0.8 to 5.0, 0.8 to 3.0, 0.8 to 1.6, 0.8 to 1.5, 0.8 to 1.4, 0.8 to 1.39, 0. 8 to 1.2, 0.8 to 1.1, 0.8 to 1.06;
1.0-5.0, 1.0-3.0, 1.0-1.6, 1.0-1.5, 1.0-1.4, 1.0-1.39. 0 to 1.2, 1.0 to 1.1, 1.0 to 1.06.
Particularly preferable ranges are, for example, 0.69 to 1.39 and 0.69 to 1.06.
　配合量に関しては、本発明の組成物には、組成物の全重量にもよるが、例えばセサミン類を１～１００ｍｇ、好ましくは１～５０ｍｇ、より好ましくは３～３０ｍｇ程度の量で配合することができる。また、γ－オリザノールを１～１００ｍｇ、好ましくは１～６０ｍｇ、より好ましくは３～３０ｍｇ程度の量で配合することができる。米胚芽油は、１～５０００ｍｇ、好ましくは１０～１０００ｍｇ、より好ましくは３０～５００ｍｇ程度の量で配合することができる。 Regarding the blending amount, although it depends on the total weight of the composition, for example, sesamin is blended in an amount of about 1 to 100 mg, preferably 1 to 50 mg, more preferably about 3 to 30 mg, depending on the total weight of the composition. Can do. Further, γ-oryzanol can be blended in an amount of about 1 to 100 mg, preferably 1 to 60 mg, more preferably about 3 to 30 mg. Rice germ oil can be blended in an amount of about 1 to 5000 mg, preferably 10 to 1000 mg, more preferably about 30 to 500 mg.
　組成物の全重量にもよるが、本発明の組成物中のセサミン類の典型的な総配合割合は、１ｗ／ｗ％以上であり、好ましくは１～５０ｗ／ｗ％、より好ましくは１～１０ｗ／ｗ％である。また、γ－オリザノールの典型的な総配合割合は、組成物全量に対し、０．１～５０ｗ／ｗ％、好ましくは０．５～３０ｗ／ｗ％、より好ましくは１～１０ｗ／ｗ％である。米胚芽油の典型的な総配合割合は、組成物全量に対し、５～９９ｗ／ｗ％、好ましくは２０～９８ｗ／ｗ％、より好ましくは５０～９５ｗ／ｗ％である。 Depending on the total weight of the composition, the typical total mixing ratio of sesamin in the composition of the present invention is 1 w / w% or more, preferably 1 to 50 w / w%, more preferably 1 to 10 w / w%. The typical total blending ratio of γ-oryzanol is 0.1 to 50 w / w%, preferably 0.5 to 30 w / w%, more preferably 1 to 10 w / w% with respect to the total amount of the composition. is there. A typical total blending ratio of rice germ oil is 5 to 99 w / w%, preferably 20 to 98 w / w%, more preferably 50 to 95 w / w% with respect to the total amount of the composition.
　尚、本発明の組成物の形態が液剤である場合には、セサミン類の典型的な総配合割合は、０．００１ｗ／ｗ％以上であり、好ましくは０．００１～０．５ｗ／ｗ％、より好ましくは０．００１～０．０５ｗ／ｗ％であり、γ－オリザノールの典型的な総配合割合は、組成物全量に対し、０．０００１～０．１ｗ／ｗ％、好ましくは０．０００５～０．０５ｗ／ｗ％、より好ましくは０．００１～０．０２ｗ／ｗ％であり、米胚芽油の典型的な総配合割合は、組成物全量に対し、０．０５～５ｗ／ｗ％、好ましくは０．１～２．５ｗ／ｗ％、より好ましくは０．２～１ｗ／ｗ％である。 When the composition of the present invention is a liquid agent, the typical total blending ratio of sesamin is 0.001 w / w% or more, preferably 0.001 to 0.5 w / w%. More preferably, it is 0.001 to 0.05 w / w%, and the typical total blending ratio of γ-oryzanol is 0.0001 to 0.1 w / w%, preferably 0. 0005 to 0.05 w / w%, more preferably 0.001 to 0.02 w / w%, and the typical total blending ratio of rice germ oil is 0.05 to 5 w / w based on the total amount of the composition %, Preferably 0.1 to 2.5 w / w%, more preferably 0.2 to 1 w / w%.
　本願発明の組成物の形態や摂取経路は特に制限されない。しかしながら、本発明においては健康増進を図ることを目的として摂取する場合、経口用組成物として摂取することが好ましい。 The form and intake route of the composition of the present invention are not particularly limited. However, in the present invention, when ingested for the purpose of promoting health, it is preferably ingested as an oral composition.
　本発明の組成物は、その効果を損なわない限り、セサミン類、γ－オリザノール、米胚芽油の他に、任意の所望成分を配合してもよい。例えば、ビタミンＥ、ビタミンＣ等のビタミン類、ミネラル類、ホルモン、栄養成分、香料などの生理活性成分のほか、製剤化において配合される乳化剤、緊張化剤（等張化剤）、緩衝剤、溶解補助剤、防腐剤、安定化剤、抗酸化剤等を適宜配合することができる。 The composition of the present invention may contain any desired component in addition to sesamins, γ-oryzanol, and rice germ oil as long as the effect is not impaired. For example, vitamins such as vitamin E and vitamin C, minerals, hormones, nutritional ingredients, physiologically active ingredients such as fragrances, emulsifiers, tonicity agents (isotonic agents), buffers, Solubilizing agents, preservatives, stabilizers, antioxidants and the like can be appropriately blended.
　本発明の組成物は、その優れた抗酸化作用のため、抗酸化剤、即ち生体内で抗酸化作用を発揮するための組成物として使用することができる。抗酸化剤の使用は、例えば、生体内での活性酸素消去、肝機能の改善、生体内での過酸化脂質生成抑制、若しくはエネルギー代謝の改善に、又は以下の疾患又は状態の予防又は防止につながり得る：肌のしわ、肌のしみ、肌のたるみ、疲労、メタボリックシンドローム、糖尿病、動脈硬化、高血圧、がん、炎症、又は老化。従って、本発明の抗酸化剤は、これらの用途においても有効である。 The composition of the present invention can be used as an antioxidant, that is, a composition for exerting an antioxidant action in vivo due to its excellent antioxidant action. The use of antioxidants is, for example, for eliminating active oxygen in vivo, improving liver function, suppressing lipid peroxide production in vivo, improving energy metabolism, or preventing or preventing the following diseases or conditions: Can lead: skin wrinkles, skin blemishes, skin sag, fatigue, metabolic syndrome, diabetes, arteriosclerosis, hypertension, cancer, inflammation, or aging. Therefore, the antioxidant of the present invention is also effective in these applications.
　体内吸収促進剤、体内吸収促進方法
　上記の通り、セサミン類にγ－オリザノール及び米胚芽油を組合せることにより、セサミン類の体内吸収性が顕著に増強される。従って、本発明は、別の側面において、γ－オリザノールと米胚芽油とを有効成分として含有するセサミン類の体内吸収促進剤である。また、本発明は、γ－オリザノールと米胚芽油とを有効成分として含有する組成物の、セサミン類の体内吸収促進剤の製造のための使用にも関する。また、本発明は、別の側面において、セサミン類の体内吸収を促進するための方法であって、当該セサミン類と、γ－オリザノールと、米胚芽油とを投与することを含む方法にも関する。投与対象には、そのような体内吸収促進を必要とする、ヒトなどの哺乳動物が含まれる。 In-vivo absorption enhancer, in-vivo absorption promotion method As described above, the in-vivo absorbability of sesamin is remarkably enhanced by combining sesamin with γ-oryzanol and rice germ oil. Therefore, in another aspect, the present invention is an in vivo absorption enhancer of sesamin containing γ-oryzanol and rice germ oil as active ingredients. The present invention also relates to the use of a composition containing γ-oryzanol and rice germ oil as active ingredients for the production of an in vivo absorption enhancer of sesamins. In another aspect, the present invention also relates to a method for promoting in vivo absorption of sesamins, the method comprising administering the sesamins, γ-oryzanol, and rice germ oil. . Subjects to be administered include mammals such as humans in need of such enhanced absorption in the body.
　当該体内吸収促進剤、組成物及び方法におけるセサミン類、γ－オリザノール、及び米胚芽油の使用比率、配合率、配合量、摂取量等は、セサミン類とγ－オリザノールと米胚芽油とを含有する組成物に関して上記した数値に基づいて適宜決定することができる。使用されるセサミン類、γ－オリザノール、及び米胚芽油の種類も同様である。 The use ratio, blending ratio, blending amount, intake amount, etc. of sesamin, γ-oryzanol and rice germ oil in the in vivo absorption enhancer, composition and method include sesamin, γ-oryzanol and rice germ oil. It can determine suitably based on the above-mentioned numerical value regarding the composition to do. The types of sesamin, γ-oryzanol and rice germ oil used are the same.
　飲食品及び医薬品
　本発明の組成物及び体内吸収促進剤は、飲食品（機能性食品、健康補助食品、栄養機能食品、特別用途食品、特定保健用食品、栄養補助食品、食事療法用食品、健康食品、サプリメント等）及び医薬品の形態で提供することが好適である。そのような飲食品及び医薬品には、セサミン類とγ－オリザノールと米胚芽油とを含む飲食組成物及び医薬組成物、及び当該組成物を含むか又は添加した飲食品及び医薬品が含まれる。また、γ－オリザノールと米胚芽油を有効成分として含有するセサミン類の体内吸収促進剤を含むか又は添加した飲食品及び医薬品も含まれる。 Food / beverage products and pharmaceuticals The composition of the present invention and the body absorption enhancer are used for food / beverage products (functional foods, health supplements, functional nutrition foods, special-purpose foods, foods for specified health use, dietary supplements, diet foods, health It is preferable to provide foods, supplements, etc.) and pharmaceuticals. Such foods and drinks and pharmaceuticals include food and drink compositions and pharmaceutical compositions containing sesamins, γ-oryzanol and rice germ oil, and foods and drinks and pharmaceuticals containing or added to the composition. Also included are foods and drinks and pharmaceuticals that contain or add sesamin absorption enhancers containing γ-oryzanol and rice germ oil as active ingredients.
　また、飲食品及び医薬品は、ペットの餌として加工したペットフードや動物飼料等、並びに動物用医薬品でもよい。 In addition, the food and drink and the medicine may be pet food processed as pet food, animal feed, and veterinary medicine.
　セサミン類とγ－オリザノールと米胚芽油とを含む飲食品及び医薬品は、血中コレステロール低下作用及び血中中性脂質低下作用、肝機能改善作用、活性酸素消去作用、Δ５不飽和化酵素阻害作用、過酸化脂質生成抑制作用、抗高血圧作用、悪酔防止作用、乳癌抑制作用等などの、セサミン類が有効であると考えられる種々の生理作用を得るために使用することができる。また、γ－オリザノール及び米胚芽油を含有するセサミン類の体内吸収促進剤である飲食品及び医薬品は、セサミン類に上記のような種々の生理作用を効率的に発揮させるために使用され得る。 Food / beverage products and pharmaceuticals containing sesamin, γ-oryzanol and rice germ oil have blood cholesterol lowering action, blood neutral lipid lowering action, liver function improving action, active oxygen scavenging action, Δ5 desaturase inhibiting action In addition, sesamin can be used to obtain various physiological actions considered to be effective, such as lipid peroxide production inhibitory action, antihypertensive action, sickness prevention action, breast cancer inhibitory action and the like. In addition, foods and drinks and pharmaceuticals which are sesamin in vivo absorption promoters containing γ-oryzanol and rice germ oil can be used to allow sesamins to efficiently exhibit the various physiological functions as described above.
　本発明の組成物を飲食品として提供する場合、その形態は、錠剤、カプセル剤、粉末剤、顆粒剤、ドリンク剤（溶液剤及び懸濁液剤が含まれる）等の健康食品の形態で提供することも、清涼飲料、茶飲料、ヨーグルトや乳酸菌飲料等の乳製品、調味料、加工食品、デザート類、菓子（例えば、ガム、キャンディ、ゼリー）等の形態で提供することも可能であるが、これらに限定されない。 When the composition of the present invention is provided as a food or drink, the form is provided in the form of health food such as tablets, capsules, powders, granules, drinks (including solutions and suspensions). It can also be provided in the form of soft drinks, tea drinks, dairy products such as yogurt and lactic acid bacteria drinks, seasonings, processed foods, desserts, confectionery (eg gum, candy, jelly), It is not limited to these.
　また、本発明の組成物を医薬品として用いる場合、その投与形態は経口投与でもよいし、注射剤等の形態で投与してもよく、各々の投与に適した製剤として公知のものを適宜用いればよい。例えば、経口投与に適した製剤には、錠剤、カプセル剤、散剤、顆粒剤、溶液剤、懸濁液剤、シロップ剤などが含まれるが、これらに限定されない。 In addition, when the composition of the present invention is used as a pharmaceutical product, the administration form may be oral administration, administration may be in the form of injections, etc., as long as a known formulation suitable for each administration is appropriately used. Good. For example, formulations suitable for oral administration include, but are not limited to, tablets, capsules, powders, granules, solutions, suspensions, syrups and the like.
　なお、セサミン類とγ－オリザノールと米胚芽油を個別に製剤化して、それらをほぼ同時に、または、一方の製剤を服用後、その効き目が持続している間に他方の製剤を服用すれば、本発明の意図するセサミン類の体内吸収促進作用が得られる。よって、γ－オリザノールと米胚芽油を一緒に、又は別々に含有するセサミン類の体内吸収促進剤とセサミン類含有組成物とを含むキット等も、本発明の意図するものである。キット中に別々に含まれる各成分は、同時に摂取しても良いし、逐次的又は別々に摂取してもよい。 In addition, if sesamin, γ-oryzanol and rice germ oil are formulated individually, and they are taken almost simultaneously, or after taking one preparation, while taking the other preparation, The in vivo absorption promoting action of sesamins intended by the present invention can be obtained. Accordingly, a kit containing a sesamin in vivo absorption enhancer and a sesamin-containing composition containing γ-oryzanol and rice germ oil together or separately is also intended by the present invention. Each component separately contained in the kit may be taken at the same time, or may be taken sequentially or separately.
　明確化のために記載すると、本明細書において上限値と下限値によって表されている数値範囲、即ち「下限値～上限値」は、それら下限値及び上限値を含む。例えば、「１～２」により表される範囲は、１及び２を含む。 For the sake of clarity, the numerical range represented by the upper limit value and the lower limit value in this specification, that is, “lower limit value to upper limit value” includes the lower limit value and the upper limit value. For example, the range represented by “1-2” includes 1 and 2.
　以下、試験例および実施例により、本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 Hereinafter, the present invention will be described more specifically with reference to test examples and examples, but the present invention is not limited thereto.
　実施例１．反転腸管モデルによる吸収性の検討
　＜実験方法＞
　ＳＤ系雄性ラット（７週齢）を試験環境で馴化させ、実験に用いた。麻酔下で開腹し脱血させた後、直ちに幽門から約１５ｃｍの小腸（主として空腸）を摘出し、２つに分割した。片側を糸で縛り、外側と内側を反転させ、調整液（内液：ＮａＣｌ １４０ｍＭ、ＣａＣｌ２　０．１ｍＭ、ＭｇＣｌ２　０．５ｍＭ、Ｄ－ｍａｎｎｏｓｅ　４０ｍＭ、Ａｓｃｏｒｂｉｃ　ａｃｉｄ　０．８ｍＭ、１０ｍＭ　Ｔｒｉｓ、ｐＨ７．４）を満たしてもう片側も縛り、５ｃｍの反転腸管を作製した。０．５ｍｌの対照溶液もしくは試験溶液をタウロコール酸ナトリウムとアルブミンを含む調整液４．５ｍｌに添加して３分間超音波にてエマルジョンを作成して、これを外液とした。反転腸管をそれぞれの外液に浸し、混合して３７℃でインキュベートした。１時間後に反転腸管を取り出し、内液を回収し重量を測定した。内液２０μｌを５０％メタノールで１０倍希釈し、遠心分離後上清をフィルターで濾過し、その中のセサミン混合物の濃度を測定した。吸収量は濃度に回収液量をかけて算出した。セサミン混合物の測定は、過去の報告（特開２００９－１５５３１２号等）を参考に、ＨＰＬＣを用いて実施した。 Example 1. Examination of absorbability by inversion intestinal model <Experimental method>
SD male rats (7 weeks old) were acclimated in the test environment and used in the experiments. After laparotomy and blood removal under anesthesia, the small intestine (mainly jejunum) of about 15 cm was immediately removed from the pylorus and divided into two. One side is tied with a thread, the outside and inside are inverted, and the adjustment solution (inner solution: NaCl 140 mM, CaCl 2 0.1 mM, MgCl 2 0.5 mM, D-mannose 40 mM, Ascorbic acid 0.8 mM, 10 mM Tris, pH 7. Satisfying 4) and tied the other side to produce a 5 cm inverted intestinal tract. 0.5 ml of the control solution or test solution was added to 4.5 ml of a preparation solution containing sodium taurocholate and albumin, and an emulsion was prepared by ultrasonication for 3 minutes, and this was used as an external solution. The inverted intestinal tract was immersed in each external solution, mixed and incubated at 37 ° C. After 1 hour, the inverted intestinal tract was taken out, the internal fluid was collected, and the weight was measured. 20 μl of the internal solution was diluted 10-fold with 50% methanol, and after centrifugation, the supernatant was filtered through a filter, and the concentration of the sesamin mixture therein was measured. The amount of absorption was calculated by multiplying the concentration by the amount of recovered liquid. The sesamin mixture was measured using HPLC with reference to past reports (Japanese Patent Application Laid-Open No. 2009-155531, etc.).
　対照群にはセサミン混合物（セサミン：エピセサミン＝１：１）１００ｍｇ、米胚芽油濃縮物（米胚芽油ガンマ３０Ｓ：γ－オリザノール３０％含有、米胚芽油７０％含有、築野食品工業株式会社）２５０ｍｇ、オリーブ油（ナカライテスク株式会社）４２５０ｍｇを加熱混合して均一にしたもの、また試験群にはセサミン混合物（セサミン：エピセサミン=１：１）１００ｍｇ、米胚芽油濃縮物（米胚芽油ガンマ３０Ｓ：γ－オリザノール３０％含有、米胚芽油７０％含有、築野食品工業株式会社）２５０ｍｇ、米胚芽油（米胚芽油ＰＲＯ－１５：γ－オリザノール１．５％、米胚芽油９８．５％含有、築野食品工業株式会社）４２５０ｍｇを加熱混合して均一にしたものを用いた。すなわち、対照群に投与した組成物においては、γ－オリザノール：（γ－オリザノール＋米胚芽油）の重量比が１：３．３であった。試験群に投与した組成物においては、γ－オリザノール：（γ－オリザノール＋米胚芽油）の重量比が１：３２．４であった。対照群、試験群共にｎ＝４で実施した。 In the control group, sesamin mixture (sesamin: episesamin = 1: 1) 100 mg, rice germ oil concentrate (rice germ oil gamma 30S: gamma-oryzanol 30%, rice germ oil 70%, Tsukino Food Industry Co., Ltd.) 250 mg, olive oil (Nacalai Tesque Co., Ltd.) 4250 mg mixed by heating, and in the test group, sesamin mixture (sesamin: episesamin = 1: 1) 100 mg, rice germ oil concentrate (rice germ oil gamma 30S: Contains γ-oryzanol 30%, rice germ oil 70%, Tsukino Food Industry Co., Ltd. 250 mg, rice germ oil (rice germ oil PRO-15: γ-oryzanol 1.5%, rice germ oil 98.5% , Tsukino Food Industry Co., Ltd.) 4250 mg heated and mixed to be uniform. That is, in the composition administered to the control group, the weight ratio of γ-oryzanol: (γ-oryzanol + rice germ oil) was 1: 3.3. In the composition administered to the test group, the weight ratio of γ-oryzanol: (γ-oryzanol + rice germ oil) was 1: 32.4. The control group and the test group were carried out with n = 4.
　＜結果＞
　結果を図１に示す。インキュベート１時間後の内液中のセサミンおよびエピセサミンの吸収量を比較すると、対照群ではセサミン１６．１９μｇ、エピセサミン１６．２３μgであったが、試験群ではセサミン２４．２９μg、エピセサミン２３．８９μgであり、セサミンおよびエピセサミン共に約１．５倍となり、顕著な吸収量の増加が確認された。以上より、セサミン類を、γ－オリザノールおよび米胚芽油と組み合わせて、さらにγ－オリザノールと米胚芽油を特定比率で用いることで、セサミン類の体内吸収が著しく促進され得ることが明らかとなった。特に、γ－オリザノールの重量の、γ－オリザノールと米胚芽油との合計重量に対する比率を、対照群の比率１：３．３よりも下げることにより、体内吸収促進効果が顕著となり得る。 <Result>
The results are shown in FIG. Comparing the absorption amounts of sesamin and episesamin in the internal solution one hour after the incubation, it was sesamin 16.19 μg and episesamin 16.23 μg in the control group, but sesamin 24.29 μg and episesamin 23.89 μg in the test group. , Sesamin and episesamin were both about 1.5 times, and a marked increase in absorption was confirmed. From the above, it has been clarified that in vivo absorption of sesamin can be significantly promoted by using sesamin in combination with γ-oryzanol and rice germ oil and further using γ-oryzanol and rice germ oil in a specific ratio. . In particular, when the ratio of the weight of γ-oryzanol to the total weight of γ-oryzanol and rice germ oil is lower than the ratio 1: 3.3 of the control group, the in vivo absorption promotion effect can be prominent.
　実施例２．処方例
　（製剤例１）顆粒剤
セサミン　　　　　　　　　　　　　　　　　　　　　　０．７５ｇ
γ－オリザノール含有米胚芽油（２５％含有）　　　　　　１０ｇ
酢酸トコフェロール　　　　　　　　　　　　　　　　　５０ｇ
無水ケイ酸　　　　　　　　　　　　　　　　　　　　　２０ｇ
トウモロコシデンプン　　　　　　　　　　　　　　　１１０ｇ
　以上を均一に混合した後に１０％ハイドロキシプロピルセルロース・エタノール溶液１００ｍｌを加え、常法通り練和し、押し出し、乾燥して顆粒剤を得た。 Example 2 Formulation Example (Formulation Example 1) Granule Sesamin 0.75g
10g rice germ oil containing γ-oryzanol (containing 25%)
Tocopherol acetate 50g
Silica anhydride 20g
110g corn starch
After uniformly mixing the above, 100 ml of 10% hydroxypropylcellulose / ethanol solution was added, kneaded as usual, extruded and dried to obtain granules.
　（製剤例２）カプセル剤
ゼラチン　　　　　　　　　　　６０.０％
グリセリン　　　　　　　　　　３０.０％
パラオキシ安息香酸メチル　　　０.１５％
パラオキシ安息香酸プロピル　　０.５１％
水　　　　　　　　　　　　　　適量
　上記成分からなるソフトカプセル剤皮の中に、以下に示す組成物を常法により充填し、１粒３６０ｍｇのソフトカプセルを得た。
セサミン　　　　　　　　　　　　　　　　１０ｍｇ
グリセリン脂肪酸エステル　　　　　　　　１５.０ｍｇ
ミツロウ　　　　　　　　　　　　　　　　１５.０ｍｇ
γ－オリザノール　　　　　　　　　　　　０．８ｍｇ
米胚芽油（γ－オリザノール１．５％含有）　２２４ｍｇ (Formulation Example 2) Capsule gelatin 60.0%
Glycerin 30.0%
Methyl paraoxybenzoate 0.15%
Propyl paraoxybenzoate 0.51%
Water Appropriate amount The following composition was filled in a soft capsule skin composed of the above-mentioned components by a conventional method to obtain 360 mg soft capsules.
Sesamin 10mg
Glycerin fatty acid ester 15.0mg
Beeswax 15.0mg
γ-Oryzanol 0.8mg
Rice germ oil (containing γ-oryzanol 1.5%) 224mg
　（製剤例３）ドリンク剤
呈味料：　　ＤＬ－酒石酸ナトリウム　　　０．１ｇ
　　　　　　コハク酸　　　　　　　　　　０．００９ｇ
甘味料：液糖　　　　　　　　　　　　８００ｇ
酸味料：クエン酸　　　　　　　　　　　１２ｇ
ビタミン：ビタミンＣ　　　　　　　　　１０ｇ
セサミン　　　　　　　　　　　　　　２．４ｇ
γ－オリザノール　　　　　　　　　　０．５ｇ
ビタミンＥ　　　　　　　　　　　　　　１０ｇ
シクロデキストリン　　　　　　　　　　　５ｇ
乳化剤　　　　　　　　　　　　　　　２００ｇ
香料　　　　　　　　　　　　　　　　　１５ｍｌ
塩化カリウム　　　　　　　　　　　　　　１ｇ
硫酸マグネシウム　　　　　　　　　　　　０．５ｇ
米胚芽油（γ－オリザノール１．５％含有）　４００ｇ
　上記成分を配合し、水を加えて１０リットルとした。このドリンク剤は、１回あたり約１００ｍｌを飲用する。 (Formulation example 3) Drink preparation flavor: DL-sodium tartrate 0.1 g
0.009 g of succinic acid
Sweetener: Liquid sugar 800g
Acidulant: Citric acid 12g
Vitamins: Vitamin C 10g
Sesamin 2.4g
γ-Oryzanol 0.5g
Vitamin E 10g
Cyclodextrin 5g
Emulsifier 200g
Fragrance 15ml
1g potassium chloride
Magnesium sulfate 0.5g
400g rice germ oil (containing 1.5% γ-oryzanol)
The above ingredients were blended and water was added to make 10 liters. About 100ml of this drink is drunk.
　（製剤例４）ドリンク剤
呈味料：　　ＤＬ－酒石酸ナトリウム　　　０．１ｇ
　　　　　　コハク酸　　　　　　　　　　０．００９ｇ
甘味料：液糖　　　　　　　　　　　　８００ｇ
酸味料：クエン酸　　　　　　　　　　　１２ｇ
ビタミン：ビタミンＣ　　　　　　　　　１０ｇ
セサミン　　　　　　　　　　　　　　　　６ｇ
γ－オリザノール　　　　　　　　　　　　２ｇ
ビタミンＥ　　　　　　　　　　　　　　１０ｇ
シクロデキストリン　　　　　　　　　　　５ｇ
乳化剤　　　　　　　　　　　　　　　　１０ｇ
香料　　　　　　　　　　　　　　　　　１５ｍｌ
塩化カリウム　　　　　　　　　　　　　　１ｇ
硫酸マグネシウム　　　　　　　　　　　　０．５ｇ
米胚芽油（γ－オリザノール１．５％含有）　２０ｇ
　上記成分を配合し、水を加えて１０リットルとした。このドリンク剤は、１回あたり約１００ｍｌを飲用する。 (Formulation Example 4) Drink agent flavor: DL-sodium tartrate 0.1 g
0.009 g of succinic acid
Sweetener: Liquid sugar 800g
Acidulant: Citric acid 12g
Vitamins: Vitamin C 10g
Sesamin 6g
γ-Oryzanol 2g
Vitamin E 10g
Cyclodextrin 5g
Emulsifier 10g
Fragrance 15ml
1g potassium chloride
Magnesium sulfate 0.5g
Rice germ oil (containing 1.5% γ-oryzanol) 20g
The above ingredients were blended and water was added to make 10 liters. About 100ml of this drink is drunk.
　実施例３．動物試験による吸収性及び抗酸化能の検討－１
　＜実験方法＞
　１０匹のＳＤ系雄性ラット（７週齢）をオリエンタルバイオサービス社より購入し、１週間試験環境で馴化させた後、対照群５匹と試験群５匹に分けた。一晩絶食の後、対照群には、セサミン混合物（セサミン：エピセサミン=１：１）８０ｍｇ、米胚芽油濃縮物（米胚芽油ガンマ３０Ｓ：γ－オリザノール３０％含有、米胚芽油７０％含有、築野食品工業株式会社）１００ｍｇ、オリーブ油（ナカライテスク株式会社）１７００ｍｇを加熱混合して均一にしたもの、また試験群にはセサミン混合物（セサミン：エピセサミン＝１：１）８０ｍｇ、米胚芽油濃縮物（米胚芽油ガンマ３０Ｓ：γ－オリザノール３０％含有、米胚芽油７０％含有、築野食品工業株式会社）１００ｍｇ、米胚芽油（米胚芽油ＰＲＯ－１５：γ－オリザノール１．５％含有、米胚芽油９８．５％含有、築野食品工業株式会社）１７００ｍｇを加熱混合して均一にしたものを体重１ｋｇあたり２ｍｌの用量でゾンデを用いて経口投与した。γ－オリザノール：（γ－オリザノール＋米胚芽油）の重量比は、対照群においては１：３．３であり、試験群においては１：３２．４であった。投与前、および投与開始の１、２、３、６、９、２４時間後に尾静脈よりヘパリン採血管にて血液を採取し、遠心分離操作（８０００ｒｐｍ、１０ｍｉｎ）により血漿サンプルを得て、血漿抗酸化能を測定した。 Example 3 FIG. Examination of absorbability and antioxidant capacity by animal test -1
<Method of experiment>
Ten SD male rats (7 weeks old) were purchased from Oriental Bioservice, and acclimated in the test environment for 1 week, and then divided into 5 control groups and 5 test groups. After overnight fasting, the control group included sesamin mixture (sesamin: episesamin = 1: 1) 80 mg, rice germ oil concentrate (rice germ oil gamma 30S: 30% γ-oryzanol, rice germ oil 70%, (Tsukino Food Industry Co., Ltd.) 100 mg, olive oil (Nacalai Tesque Co., Ltd.) 1700 mg mixed by heating, and in the test group, sesamin mixture (sesamin: episesamin = 1: 1) 80 mg, rice germ oil concentrate (Rice germ oil gamma 30S: 30% γ-oryzanol, 70% rice germ oil, Tsukino Food Industry Co., Ltd.) 100 mg, rice germ oil (rice germ oil PRO-15: 1.5% γ-oryzanol) Rice germ oil containing 98.5%, Tsukino Food Industry Co., Ltd.) 1700 mg of heat-mixed and homogenized using a sonde at a dose of 2 ml per kg body weight Orally administered. The weight ratio of γ-oryzanol: (γ-oryzanol + rice germ oil) was 1: 3.3 in the control group and 1: 32.4 in the test group. Before administration and 1, 2, 3, 6, 9, 24 hours after the start of administration, blood was collected from the tail vein with a heparin blood collection tube, and a plasma sample was obtained by centrifugation (8000 rpm, 10 min). The oxidation ability was measured.
　血漿抗酸化能の測定にはＯＲＡＣ（Ｏｘｙｇｅｎ　Ｒａｄｉｃａｌ　Ａｂｓｏｒｂａｎｃｅ　Ｃａｐａｃｉｔｙ法）（文献Ｆｒｅｅ　Ｒａｄｉｃ．　Ｂｉｏｌ.　Ｍｅｄ.１４（３）,３０３－３１１（１９９３）、Ｊ　Ａｇｒｉｃ　Ｆｏｏｄ　Ｃｈｅｍ.４９（１０）,４６１９－４６２６（２００１）、Ｊ　Ａｇｒｉｃ　Ｆｏｏｄ　Ｃｈｅｍ.５０（７）,１８１５－１８２１（２００２）、Ｊ　Ａｇｒｉｃ　Ｆｏｏｄ　Ｃｈｅｍ.５３（１０），４２９０－４３０２（２００５）等を参照）を用いた。高いＯＲＡＣ値は、高い抗酸化能を示す。 For the measurement of plasma antioxidant capacity, ORAC (Oxygen Radical Absorbance Capacity method) (reference: Free Radic. Biol. Med. 14 (3), 303-311 (1993), J Agric Food Chem. 49 (10), 4619-4626 (2001), J Agric Food Chem. 50 (7), 1815-1821 (2002), J Agric Food Chem. 53 (10), 4290-4302 (2005), etc.) were used. A high ORAC value indicates a high antioxidant capacity.
　＜結果＞
　動物ごとに投与前の血液ＯＲＡＣ値（μｍｏｌ　ＴＥ／Ｌ）と、投与開始後に採血したサンプルの血液ＯＲＡＣ値（μｍｏｌ　ＴＥ／Ｌ）との差を算出した。この値をΔＯＲＡＣ値と示すことにする。ΔＯＲＡＣ値のＡＵＣを示したのが図２である。図２より、対照群に比べて試験群のΔＯＲＡＣ値のＡＵＣが顕著に上昇していることが確認された。以上より、γ－オリザノールの重量の、γ－オリザノールと米胚芽油との合計重量に対する比率を、対照群の比率１：３．３よりも下げることにより、抗酸化能が著しく上昇することが明らかとなった。セサミン類は生体内で抗酸化作用を示すことが知られているため、この抗酸化能の上昇は、セサミン類の体内吸収の促進を裏付けるものと考えられる。 <Result>
The difference between the blood ORAC value (μmol TE / L) before administration and the blood ORAC value (μmol TE / L) of the sample collected after the start of administration was calculated for each animal. This value will be denoted as ΔORAC value. FIG. 2 shows the AUC of the ΔORAC value. From FIG. 2, it was confirmed that the AUC of the ΔORAC value of the test group was significantly increased as compared with the control group. From the above, it is clear that the antioxidant capacity is remarkably increased by reducing the ratio of the weight of γ-oryzanol to the total weight of γ-oryzanol and rice germ oil from the ratio of 1: 3.3 in the control group. It became. Since sesamin is known to exhibit an antioxidant action in vivo, this increase in antioxidant capacity is considered to support the promotion of in vivo absorption of sesamin.
　実施例４．動物試験による吸収性及び抗酸化能の検討－２
　＜実験方法＞
　１０匹のＳＤ系雄性ラット（７週齢）をオリエンタルバイオサービス社より購入し、１週間試験環境で馴化させた後、対照群５匹と試験群５匹に分けた。一晩絶食の後、対照群には、セサミン混合物（セサミン：エピセサミン=１：１）８０ｍｇ、米胚芽油（米胚芽油ＰＲＯ－１５：γ―オリザノール１．５％含有、米胚芽油９８．５％含有、築野食品工業株式会社）１２１８ｍｇ、オリーブ油（ナカライテスク株式会社）３２８２ｍｇを加熱混合して均一にしたもの、また試験群にはセサミン混合物（セサミン：エピセサミン＝１：１）８０ｍｇ、米胚芽油濃縮物（米胚芽油ガンマ３０Ｓ：γ―オリザノール３０％含有、米胚芽油７０％含有、築野食品工業株式会社)６０ｍｇ、米胚芽油（米胚芽油ＰＲＯ－１５：γ―オリザノール１．５％含有、米胚芽油９８．５％含有、築野食品工業株式会社）４４４０ｍｇを加熱混合して均一にしたものを体重１ｋｇあたり５ｍｌの用量でゾンデを用いて経口投与した。γ－オリザノール：（γ－オリザノール＋米胚芽油）の重量比は、対照群においては１：６７であり、試験群においては１：５３．２であった。投与前と、投与開始の１、３、６、９、２４時間後に尾静脈よりヘパリン採血管にて血液を採取し、遠心分離操作（８０００ｒｐｍ、１０ｍｉｎ）により血漿サンプルを得て、血漿抗酸化能を測定した。血漿抗酸化能の測定は、実施例３と同様の方法で実施した。 Example 4 Examination of absorbability and antioxidant capacity by animal test-2
<Method of experiment>
Ten SD male rats (7 weeks old) were purchased from Oriental Bioservice, and acclimated in the test environment for 1 week, and then divided into 5 control groups and 5 test groups. After overnight fasting, the control group contained 80 mg of sesamin mixture (sesamin: episesamin = 1: 1), rice germ oil (rice germ oil PRO-15: γ-oryzanol 1.5%, rice germ oil 98.5) % Content, Tsukino Food Industry Co., Ltd.) 1218 mg, olive oil (Nacalai Tesque Co., Ltd.) 3282 mg mixed by heating, and in the test group, sesamin mixture (sesamin: episesamin = 1: 1) 80 mg, rice germ Oil concentrate (rice germ oil gamma 30S: containing γ-oryzanol 30%, rice germ oil 70% contained, Tsukino Food Industry Co., Ltd.) 60 mg, rice germ oil (rice germ oil PRO-15: γ-oryzanol 1.5 % Containing, rice germ oil 98.5% containing, Tsukino Food Industry Co., Ltd.) 4440 mg was heated and mixed uniformly using a sonde at a dose of 5 ml per kg body weight It was administered. The weight ratio of γ-oryzanol: (γ-oryzanol + rice germ oil) was 1:67 in the control group and 1: 53.2 in the test group. Before administration and 1, 3, 6, 9, 24 hours after the start of administration, blood was collected from the tail vein with a heparin blood collection tube, and a plasma sample was obtained by centrifugation (8000 rpm, 10 min). Was measured. Plasma antioxidant capacity was measured in the same manner as in Example 3.
　＜結果＞
　ΔＯＲＡＣ値（定義は上述の通り）のＡＵＣを示したのが図３である。図３から、対照群に比べて試験群のΔＯＲＡＣ値のＡＵＣが顕著に上昇していることが確認された。以上より、γ－オリザノールの重量の、γ－オリザノールと米胚芽油との合計重量に対する比率を、対照群の比率１：６７よりも上げることにより、抗酸化能が著しく上昇することが明らかとなった。この抗酸化能の上昇は、セサミン類の体内吸収の促進を裏付けるものと考えられる。 <Result>
FIG. 3 shows the AUC of the ΔORAC value (the definition is as described above). From FIG. 3, it was confirmed that the AUC of the ΔORAC value of the test group was significantly increased as compared with the control group. From the above, it has been clarified that the antioxidant capacity is remarkably increased by increasing the ratio of the weight of γ-oryzanol to the total weight of γ-oryzanol and rice germ oil from the ratio of 1:67 in the control group. It was. This increase in antioxidant capacity is thought to support the promotion of sesamin absorption in the body.

Claims (14)

  1. 　少なくとも一種のセサミン類と、少なくとも一種のγ－オリザノールと、米胚芽油とを含有する組成物であって、当該γ－オリザノールの総重量：（当該γ－オリザノールの総重量と当該米胚芽油の重量の合計量）＝１：４～１：６６である、組成物。 A composition comprising at least one sesamin, at least one γ-oryzanol and rice germ oil, wherein the total weight of the γ-oryzanol: (the total weight of the γ-oryzanol and the rice germ oil Total composition of weight) = 1: 4 to 1:66.
  2. 　前記γ－オリザノールの総重量：（前記γ－オリザノールの総重量と前記米胚芽油の重量の合計量）＝１：２０～１：６０である、請求項１に記載の組成物。 The composition according to claim 1, wherein the total weight of the γ-oryzanol: (the total amount of the total weight of the γ-oryzanol and the weight of the rice germ oil) = 1: 20 to 1:60.
  3. 　前記セサミン類の総重量を１とした場合の前記γ－オリザノールの総重量が０．３以上である請求項１又は２に記載の組成物。 3. The composition according to claim 1, wherein the total weight of the γ-oryzanol is 0.3 or more when the total weight of the sesamins is 1.
  4. 　前記セサミン類がセサミンおよび／またはエピセサミンである、請求項１～３のいずれかに記載の組成物。 The composition according to any one of claims 1 to 3, wherein the sesamin is sesamin and / or episesamin.
  5. 　経口用である請求項１～４のいずれかに記載の組成物。 The composition according to any one of claims 1 to 4, which is for oral use.
  6. 　飲食物である請求項１～５のいずれかに記載の組成物。 The composition according to any one of claims 1 to 5, which is a food or drink.
  7. 　抗酸化剤である、請求項１～６のいずれかに記載の組成物。 The composition according to any one of claims 1 to 6, which is an antioxidant.
  8. 　少なくとも一種のγ－オリザノールと米胚芽油とを有効成分として含有する、少なくとも一種のセサミン類の体内吸収促進剤。 ¡At least one sesamin absorption enhancer containing at least one γ-oryzanol and rice germ oil as active ingredients.
  9. 　少なくとも一種のγ－オリザノールと米胚芽油とを有効成分として含有する組成物の、少なくとも一種のセサミン類の体内吸収促進剤の製造のための使用。 Use of a composition containing at least one γ-oryzanol and rice germ oil as active ingredients for the production of at least one sesamin in vivo absorption enhancer.
  10. 　前記γ－オリザノールの総重量：（前記γ－オリザノールの総重量と前記米胚芽油の重量の合計量）＝１：４～１：６６である、請求項８に記載の体内吸収促進剤又は請求項９に記載の使用。 The in-vivo absorption enhancer or claim according to claim 8, wherein the total weight of the γ-oryzanol: (the total amount of the total weight of the γ-oryzanol and the weight of the rice germ oil) = 1: 4 to 1:66. Item 10. Use according to Item 9.
  11. 　前記γ－オリザノールの総重量：（前記γ－オリザノールの総重量と前記米胚芽油の重量の合計量）＝１：２０～１：６０である、請求項１０に記載の体内吸収促進剤又は使用。 The in-vivo absorption enhancer or use according to claim 10, wherein the total weight of the γ-oryzanol: (the total amount of the total weight of the γ-oryzanol and the weight of the rice germ oil) = 1: 20 to 1:60. .
  12. 　前記セサミン類の総重量を１とした場合の前記γ－オリザノールの総重量が０．３以上である、請求項８～１１のいずれかに記載の体内吸収促進剤又は使用。 The in-vivo absorption enhancer or use according to any one of claims 8 to 11, wherein the total weight of the γ-oryzanol is 0.3 or more when the total weight of the sesamin is 1.
  13. 　前記セサミン類がセサミンおよび／またはエピセサミンである、請求項８～１２のいずれかに記載の体内吸収促進剤又は使用。 The in-vivo absorption enhancer or use according to any one of claims 8 to 12, wherein the sesamin is sesamin and / or episesamin.
  14. 　前記体内吸収促進剤が経口用である、請求項８～１３のいずれかに記載の体内吸収促進剤又は使用。 The in vivo absorption enhancer or use according to any one of claims 8 to 13, wherein the in vivo absorption enhancer is for oral use.
PCT/JP2013/066033 2012-06-14 2013-06-11 COMPOSITION COMPRISING SESAMIN COMPOUND, γ-ORIZANOL AND RICE GERM OIL WO2013187391A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201380031469.5A CN104394864B (en) 2012-06-14 2013-06-11 Compositions containing sesamin-class compounds, gamma oryzanol and rice germ oil
JP2014521336A JP6157463B2 (en) 2012-06-14 2013-06-11 Composition containing sesamin, γ-oryzanol and rice germ oil
HK15105560.2A HK1204936A1 (en) 2012-06-14 2015-06-11 Composition comprising sesamin compound, orizanol and rice germ oil

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012135034 2012-06-14
JP2012-135034 2012-06-14

Publications (1)

Publication Number Publication Date
WO2013187391A1 true WO2013187391A1 (en) 2013-12-19

Family

ID=49758213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/066033 WO2013187391A1 (en) 2012-06-14 2013-06-11 COMPOSITION COMPRISING SESAMIN COMPOUND, γ-ORIZANOL AND RICE GERM OIL

Country Status (5)

Country Link
JP (1) JP6157463B2 (en)
CN (1) CN104394864B (en)
HK (1) HK1204936A1 (en)
TW (1) TWI603732B (en)
WO (1) WO2013187391A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015093484A1 (en) * 2013-12-16 2015-06-25 サントリーホールディングス株式会社 Composition having high sesamin content
JP2019014697A (en) * 2017-07-11 2019-01-31 株式会社アンチエイジング・プロ Compositions for enhancing polyphenol absorption, methods for improving in vivo polyphenol absorption and compositions for oral intake
JP2019196340A (en) * 2018-05-10 2019-11-14 亀井　淳三 Inclusion composite of sesaminol and cyclodextrin and its production method

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016152846A1 (en) * 2015-03-23 2016-09-29 サントリーホールディングス株式会社 Composition for improving circadian rhythm

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06227977A (en) * 1993-02-01 1994-08-16 Suntory Ltd Active oxygen eliminating agent
JPH06340889A (en) * 1993-05-31 1994-12-13 Tokyo Yushi Kogyo Kk Production of oryzanol-rich rice bran oil
JPH07255393A (en) * 1994-03-24 1995-10-09 Chikuno Shokuhin Kogyo Kk Agent for improving quality of boiled rice
WO2006070856A1 (en) * 2004-12-28 2006-07-06 Suntory Limited Sesamin/episesamin compositions
JP2007124917A (en) * 2005-11-01 2007-05-24 Chikuno Shokuhin Kogyo Kk Method for producing rice oil richly containing oryzanol, and usage of the rice oil
JP2009073749A (en) * 2007-09-19 2009-04-09 Suntory Ltd COMPOSITION CONTAINING SESAMIN COMPOUNDS AND gamma-ORYZANOL
WO2010074220A1 (en) * 2008-12-26 2010-07-01 サントリーホールディングス株式会社 Composition containing sesamins and epigallocatechin gallate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI406867B (en) * 2005-09-30 2013-09-01 Suntory Holdings Ltd And a method for producing a high content of episesamin

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06227977A (en) * 1993-02-01 1994-08-16 Suntory Ltd Active oxygen eliminating agent
JPH06340889A (en) * 1993-05-31 1994-12-13 Tokyo Yushi Kogyo Kk Production of oryzanol-rich rice bran oil
JPH07255393A (en) * 1994-03-24 1995-10-09 Chikuno Shokuhin Kogyo Kk Agent for improving quality of boiled rice
WO2006070856A1 (en) * 2004-12-28 2006-07-06 Suntory Limited Sesamin/episesamin compositions
JP2007124917A (en) * 2005-11-01 2007-05-24 Chikuno Shokuhin Kogyo Kk Method for producing rice oil richly containing oryzanol, and usage of the rice oil
JP2009073749A (en) * 2007-09-19 2009-04-09 Suntory Ltd COMPOSITION CONTAINING SESAMIN COMPOUNDS AND gamma-ORYZANOL
WO2010074220A1 (en) * 2008-12-26 2010-07-01 サントリーホールディングス株式会社 Composition containing sesamins and epigallocatechin gallate

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015093484A1 (en) * 2013-12-16 2015-06-25 サントリーホールディングス株式会社 Composition having high sesamin content
JP2019014697A (en) * 2017-07-11 2019-01-31 株式会社アンチエイジング・プロ Compositions for enhancing polyphenol absorption, methods for improving in vivo polyphenol absorption and compositions for oral intake
JP2019196340A (en) * 2018-05-10 2019-11-14 亀井　淳三 Inclusion composite of sesaminol and cyclodextrin and its production method
JP7079931B2 (en) 2018-05-10 2022-06-03 淳三 亀井 Encapsulation complex of sesaminol and cyclodextrin and its production method

Also Published As

Publication number Publication date
JPWO2013187391A1 (en) 2016-02-04
JP6157463B2 (en) 2017-07-05
TWI603732B (en) 2017-11-01
CN104394864B (en) 2016-10-05
CN104394864A (en) 2015-03-04
HK1204936A1 (en) 2015-12-11
TW201410238A (en) 2014-03-16

Similar Documents

Publication Publication Date Title
KR101262686B1 (en) Composition for body fat reduction
JP5686496B2 (en) Metabolic syndrome improvement / prevention composition
JP4995567B2 (en) Sesamin / episesamin composition
EP3590356A1 (en) Composition for controlling and reducing blood cholesterol levels
WO2011077800A1 (en) Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages
JP2009173634A (en) LIPID ABSORPTION INHIBITOR CONTAINING POLY-gamma-GLUTAMIC ACID
JP6157463B2 (en) Composition containing sesamin, γ-oryzanol and rice germ oil
JP5276316B2 (en) Composition containing sesamin and quercetin glycoside
JP2006347927A (en) Fatigue-improving agent
JP5547891B2 (en) Composition containing sesamin and epigallocatechin gallate
JP5280029B2 (en) Composition containing sesamin and γ-oryzanol
JP5584411B2 (en) Homocysteine lowering composition
JP2022159178A (en) Anti-aging composition
JP6537975B2 (en) Composition containing high sesamin
TW201424743A (en) Igf-1 production promoter
JP2006022064A (en) Prophylactic and/or ameliorative agent for arteriosclerosis, functional food, or cosmetic
JP2009155278A (en) Hyperhomocystemia improving agent
JP2010254590A (en) Pancreatic lipase inhibitor
JP2007246488A (en) Peptic ulcer ameliorating composition
JP2006083106A (en) Agent having inhibition action on rising of blood neutral fat concentration and food and drink
JP2009179592A (en) Qol improver

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13804214

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014521336

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13804214

Country of ref document: EP

Kind code of ref document: A1